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ABSTRACT
CHARACTERIZATION OF ADIPOSITY AND INFLAMMATION GENETIC
PLEIOTROPY UNDERLYING CARDIOVASCULAR RISK FACTORS IN
HISPANICS
Mohammad Yaser (Anwar)
11/30/2020
The observed overlap between genetic variants associated with both adiposity and
inflammatory markers suggests that changes in both adiposity and inflammation could be
partially mediated by common pathways. The pervasive but sparsely characterized
“pleiotropic” genetic variants associated with both adiposity and inflammation have been
hypothesized to provide insight into the shared biology. This study explored and
characterized the genetic pleiotropy underpinning adiposity and inflammation using
genetic and phenotypic observations from the Cameron County Hispanic Cohort (CCHC).
A total of 3,313 samples and >9 million single nucleotide polymorphisms (SNPs) were
examined in this study. Mixed model genome-wide association studies (GWAS) were
performed for 9 phenotypes including C-reactive protein (CRP), Interleukin (IL)-6, IL-8,
fibrinogen, body mass index (BMI), waist circumference (WC) in males and females, and
waist to hip ratio (WHR) in males and females (separately). GWAS for WHR and WC
were meta-analyzed to obtain sex-combined results. Pleiotropy assessment was completed
using adaptive Sum of Powered Score (aSPU) test. Three genetic loci with evidence of
pleiotropy on chromosome 3, 12 and 18 were fine-mapped to distinguish the set of likely
v

causal variants. Causal mediation analysis was used to assess whether likely causal variants
were independently associated with both inflammation and adiposity.
At least 3 signals, on chromosomes 3, 12, and 12, were identified that suggested the
presence of SNPs with strong pleiotropic p-values (< 5 × 10−6). The fine-mapping of these
three suspected pleiotropic regions distinguished 22 variants with posterior causality
probabilities greater than 50%. The mediation analysis indicated that rs60505812, on
chromosome 3, was independently associated with both an inflammatory marker (IL-6)
and an adiposity measure (BMI). For the variant rs73093474, on chromosome 12, results
indicated both a direct association with CRP and an indirect association (via WHR).
The identification of likely pleiotropic variants indicated that 1) a considerable degree of
overlapping genetic pleiotropy exists between adiposity and inflammation, and 2) evidence
exists to support both the direct and indirect pleiotropy. The results showed the potential
of these genetic variants to provide biological insight, intended to improve the
cardiovascular health of the Hispanics, and by extension all populations.
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INTRODUCTION AND BACKGROUND
This chapter presents background information on the epidemiologic, pathophysiologic
and genetic aspects of obesity and associated cardiovascular risk factors, particularly in the
context of Hispanic/Latino populations. Biologic discussions focus on associations and
functional overlaps between adiposity and inflammation that promote adverse
cardiovascular outcomes. The review emphasizes gaps in the current literature on genetic
factors underpinning biologic pathways affecting adiposity and inflammation in
Hispanic/Latinos, and concludes with the scientific aims of the dissertation work.
1. Epidemiology
1.1. Obesity trends
Although a struggle with undernutrition has been a defining feature for most of human
history, the industrial revolution resulted in the explosive growth of agricultural
productivity over the last two and half centuries, resulting in a relative abundance of food
that has significantly contributed to the well-being of societies. Records from industrialized
countries show that the average height1 and weight2 of individuals has progressively
increased throughout the 19th and the first half of the 20th century.
However, continued uptake of high calorie foods coupled with changes in lifestyles and
environmental settings, especially during the latter half of the 20th century, have gradually
tipped the balance toward obesity. The populations in more wealthy parts of the world have
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begun to gain weight at levels that are disproportionate to the gains made in height3. At the
dawn of the new millennium, humans passed a landmark point when adults with excess
weight outnumbered those who were underweight4. Today, obesity is a major public health
challenge5.
Even though obesity figures vary between countries, due to differences in socioeconomic
characteristics and the speed of epidemic transition [away from infections’ dominated
landscape toward the rise in metabolic diseases]6, recent decades have seen linear upward
trend in the prevalence of overweight and obesity almost everywhere7. Between 1980 and
2013, the average proportion of overweight increased by one-third, in both men and
women, globally8. A review of over 2,000 population-based studies published between
1985 and 2017 showed that body mass index (BMI) values, defined as weight (in
kilograms) over height squared (in meters), increased from 22.6 to 24.7 in women and from
22.2 to 24.4 in men9.
This rising trajectory in obesity appears to include all age groups. Based on a pooled
analysis of approximately 2,500 population-based studies, including 128 million
individuals aged 5 years and older, the average estimated global prevalence of obesity
among children has increased 8-fold, from just under 1% in 1975 to approximately 8% in
201610. In the United States, estimates have shown that approximately 69% of adults are
classified as overweight (BMI ≥ 25), 35% are obese (BMI ≥ 30), and 14.5% are moderately
to extremely obese (BMI ≥ 35) 11.
However, average numbers do not reflect the underlying complexities associated with
obesity prevalence. At the subnational level, significant disparities in the distribution of
overweight and obesity exist among various ethnic and socioeconomic12,13. A higher
2

proportion of Hispanic Americans appear to suffer from overweight and obesity, with a
greater than 12% increase in the prevalence of overweight and a greater than 21% increase
in the prevalence of all-type obesity compared with the overall mean for the adult
population (>20 years age)11. A review of the National Health and Nutrition Examination
Survey (NHANEs) biannual reports between 1999-2018 revealed larger annual percentage
point increases in obesity among Hispanics compared with non-Hispanics, with severe
obesity now occurring in over 10% for this ethnic group14. It should be noted that increase
in obesity is not limited in Hispanic Americans but similarly noted in other countries with
majority Latino populations15, with unequal distribution that disproportionately affects
those at lower levels of socioeconomic status16.
1.2. Public health significance
Increased obesity is an important public health issue due to the associations between
obesity and various adverse health outcomes17,18. Central obesity, in which the excessive
accumulation of weight occurs in the abdominal region, is a known risk factor for serious
diseases19, and has been associated with insulin resistance20, high blood pressure21,
dyslipidemia22, and metabolic hormones disorders18. These metabolic disorders, in turn,
increase susceptibility to cardiovascular diseases23, often with fatal consequences.
Unsurprisingly, given the elevated trends in obesity, the prevalence of cardiovascular risk
factors is also higher among ethnic minorities, including Hispanics24. For example, the ageadjusted prevalence ratio of diabetes was >2.5 times higher in Hispanics than in nonHispanic whites, in one recent survey25; another study suggested that as many as two in
three Hispanic adults present with abnormal levels of lipids26.
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Yet, despite the elevated prevalence of various metabolic risk factors, Hispanics also
appear to have longer life spans and suffer from lower rates of cardiovascular diseaseassociated mortality27,28. Statistics from NHANES from 1988 to 2006 vividly illustrate the
reduced mortality rate in this group compared with other groups (e.g. Hazard ratio 0.42 vs
Non-Hispanic Whites among ≥ 50 years old)29. Various factors, including immigration of
healthy individuals27, a legume- and fruit-based dietary pattern, supportive social and
family structures, the unreliability of the data, and the Salmon bias, which describes the
tendency for older, unhealthy individuals to return to their original countries30, have been
suggested as possible explanations for this “Hispanic paradox”31.
Whether this paradox exists32 and what factors may explain it is an active area of
research, rife with arguments and counterarguments. However, the persistence of a lower
mortality rate among Hispanics, even in studies that have attempted to control for
socioeconomic factors33, has resulted in a focus on the important but sparsely explored
contributions of genetic ancestry to this paradox34.
2. Pathophysiology
Increasing body weight steadily taxes the body’s physiological capacities35, eventually
causing major disorders36. Altered pulmonary parameters37, the expansion of cardiac
output, increased sympathetic nervous system activities38, increased systolic and diastolic
blood pressure39, elevated sodium retention40, and the attenuation of immunity41 are some
of the notable consequences of increased body weight. The pathophysiological changes
that are triggered by excess weight can affect multiple organs and systems, leading to
adverse outcomes in brain42, reproductive43, liver44, and kidney functions45, among others.
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The deleterious effects on the heart and vascular system are particularly concerning46
because the obese population features a significantly higher mortality rates associated with
cardiovascular diseases, with one studying reporting a hazard ratio as high as 2.21 among
those with body mass index (BMI)≥40, compared to normal weight (20≤BMI<25)
individuals47, even as the BMI is not an ideal predictor of the cardiovascular diseases48.
The United States National Vital Statistics report in 2017 showed that 23% of all deaths
could be attributed to heart diseases, making heart disease the top-ranked cause of
mortality, ahead of all types of malignant neoplasia49.
2.1. Obesity-cardiovascular system association mechanisms
The precise mechanisms that link obesity with cardiovascular risk factors remain
unknown, although many hypotheses have been generated50-52, all of which could partially
or substantially contribute to this association. For instance, one proposition is that the
obesity-induced decrease in insulin sensitivity promotes increased arterial stiffness53.
Insulin-resistance reduces endothelium-dependent vasodilation53, possibly through nitric
oxide-dependent processes that act as physiological regulators of vascular tone54 and
induce smooth muscle proliferation and migration54.
Abnormal kidney function and the resulting impacts on elevated blood pressure and
hemodynamic imbalance is another area of research focus55. Obesity increases tubular
reabsorption, shifting pressure natriuresis (sodium excretion) toward higher blood pressure
to maintain the water-sodium balance56. Elevated reabsorption appears to be mediated
through the activation of the renin-angiotensin system, and the buildup of adipose tissue
around the kidney and increased extracellular matrix levels within the kidney can cause
medullary compression, altering the intrarenal mechanical forces57 (Figure 1.1). Obesity is
5

also associated with tangible renal vasodilation and higher glomerular filtration rates58,
which can increase sodium reabsorption.
Nonetheless, the focus of the majority of research on obesity and cardiovascular risk
factors has been on adipose tissue. Changes in the local distribution59 and metabolic
characteristics of adipose tissue60,61 play decisive roles in the association between obesity
and adverse cardiovascular outcomes. The regulation of adipose tissue is a delicate process,
and disruptions in adipose regulation can result in detrimental health effects, particularly
in visceral and ectopic adipose tissue, which are particularly sensitive to overnutrition62. In
response to sedentary lifestyle conditions63, genetic predispositions64 or exposure to
malignant environmental factors65, the rapid or sustained accumulation of lipids can disrupt
the differentiation of preadipocytes and accelerating the formation of larger, dysfunctional
adipocytes66,67 (Figure 1.2).
2.2. Adiposity and inflammation
The associations between obesity and metabolic irregularities are often attributed to
inflammatory responses induced by adipose tissue68,69. In humans, similar to other
mammals, adipose tissues exist in two forms: white adipose tissue and brown adipose
tissue. Brown adipose tissue is found primarily in (human) neonates and plays a significant
role in the regulation of body temperature through non-shivering thermogenesis during the
earlier years of life. White adipose tissue, on the other hand, is thought to be the site of
energy storage when a positive imbalance exists between energy intake and expenditure.
Adipose tissue also contains preadipocytes, endothelial cells, fibroblasts, leukocytes, and
macrophages. Energy, primarily in the form of glucose and fatty acids, is converted to
lipids through a well-characterized lipogenesis process70.
6

Adipocytes can expand in size (hypertrophy) and numbers (hyperplasia) to accommodate
increased fat storage needs in cases of positive energy imbalance71 to maintain energy
homeostasis. Adipose tissue expansion creates the need for insulin, which is an essential
peptide secreted from beta-cells in the pancreas that regulates the absorption of glucose
from the bloodstream into the liver, skeletal muscles, and adipocytes.
Sustained anabolic activities, such as growth and differentiation, necessitate a steadier
supply of insulin as an adaptive response to excess energy or in response to underlying
disease. This intensely pushes the closed-loop of the adipocyte-brain axis, which controls
the feedback process72, and adipocytes respond with increased hyperplasia and
hypertrophic changes.
Enlarged adipocytes feature altered lipolytic profiles, which can be attributed to the
enrichment of regulatory proteins, including lipase and perilipin, which are distal in the
lipolytic cascade73. These cells have also been shown to be resistant to the lipopenic (blood
lipid decreasing) actions of leptin74, a hormone that is made in adipose cells (beside
enterocytes) and contributes to the regulation of energy balance by inhibiting the hunger
sensation75.
Ability of enlarged adipocytes to synthesize adiponectin is decreased compared with
normal adipocytes, which impairs fat oxidation and glucose regulation and amelioration of
inflammatory activities76. Simultaneously, highly active hypertrophied adipocytes exhibit
distorted cytokine secretion characteristics77. They also promote noticeable increase in the
circulating levels of several cytokines, including interleukin (IL)-6 and IL-8, noticeably
increase78,79.
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Adding to the complexity of inflammatory reactions, the physical expansion of cells
triggers increased blood flow, resulting in the attraction of macrophages through several
signals, including monocyte chemoattractant protein 1 (MCP1)80 and increased apoptotic
adipocytes66. In experimental studies, CD8+ T-cells are attracted to and infiltrate obese
adipose tissue, which, in turn, facilitates the recruitment and activation of macrophages to
this tissue81. increased macrophage presence in adipose tissue is associated with increased
obesity82.
Within pro-inflammatory milieu of expanded adipose tissue, in which increased
concentrations of macrophages are admixed with lipolytic and apoptotic adipocytes, crosstalk between these two cell types can promote positive feedback loops, resulting in the
amplification of adverse metabolic and inflammatory actions, mediated by an increase in
the levels of circulating inflammation markers83,50 (Figure 1.3). Moreover, adipocytesecreted cytokines, including IL-6, are key drivers of C-reactive protein (CRP) production
in the liver (through direct liver access via the portal system84). As a result, CRP is often
used as a significant predictor of cardiovascular diseases85.
Enhanced cytokine levels result in the increased production of free fatty acids, which are
potent activators of the Toll-like receptor family86. Toll-like receptors are pattern
recognition receptors that activate a variety of intracellular signaling pathways, including
the activation of nuclear factor-kappa B (NF-kB) and inflammatory cytokine production,
which are responsible for activating innate immunity87 and triggering the inception of
atheromatic processes.
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2.3. Inflammation as a possible adiposity precursor
Although most biological research presupposes adiposity to be the trigger for the
inflammatory process, some indications have suggested that the adiposity–inflammation
relationship could also move in the other direction. For example, compelling evidence
suggests that inflammation-induced insulin resistance may dysregulate glucose uptake by
adipocytes and promote or exacerbate the accumulation and inflammation of adipose
tissue88. Insulin resistance-induced hyperinsulinemia can create anabolic pressure89,
triggering hyperplastic and hypertrophic changes in adipose tissues to alleviate glucose
accumulation90. If sustained, these cells ultimately reach a tipping point, when further
anabolic pressures cannot be accommodated due to constraints on the physical expansion
of cells and tissues.
Beside insulin resistance induced adiposity, analysis of inflammatory markers in over
2,000 non-diabetic, middle-aged men found that the highest levels of inflammatory
markers at baseline were predictive of weight gain over the 6 years of the study follow-up,
regardless of body weight at the start of the study91.
Specific dietary patterns, particularly those high in sugar and saturated fats, have been
reported to cause inflammation in the hypothalamus, resulting in leptin resistance, a
precursor event to appetite dysregulation and the altered metabolism of fat and glucose92.
A similar pattern of leptin resistance was also observed in experimental studies with rats93.
Microbiota and bacteria-induced inflammation that precedes obesity is an active area of
research, in which structural changes in the permeability of the gut may promote the
selective uptake of nutritional components94-96.
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2.4. A case for overlap in the underlying functional mechanism
Some of the relationships described above have been suggested to form a circular loop,
in which weight gain causes inflammation, resulting in metabolic/structural alterations that,
in turn, cause further fat accumulation. Such self-sustained feedback mechanisms have
previously been suggested97 and merit attention in adiposity–inflammation association
studies (Figure 1.4).
Although most of the studies included in this review implicitly assume that these
feedback mechanisms move towards a pathophysiological direction, the origin of the
trigger remains unclear. The sophisticated and complex natures of both inflammation and
adiposity suggest a nuanced underlying mechanism, one that may be induced by certain
changes in either adiposity or inflammation and may be mediated by common molecular
pathways that result in variations in both domains, indicating a level of interrelatedness
between these two domains, linked by some shared biological underpinning. A
comprehensive investigative approach remains necessary to discern these relationships by
incorporating traditional laboratory-based assessments with genetic insights at both the
population and molecular level.
3. Genetics of obesity and inflammation
Although the role played by genetics in the expression of biological traits has long been
accepted, scientists have only recently begun to contemplate the exact mechanisms that
link heritable elements with the expression of physiological98 and other phenotypes99. The
widespread availability of DNA sequencing and genotyping techniques and the
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development of statistical tools that take advantage of ever-increasing computational
power has resulted in the advent of GWAS.
In contrast with approaches that test pre-specified regions, the hypothesis-independent
GWAS approach scans millions of variants throughout the genome, examining their
associations with phenotypic variations. First adopted in early 2000, GWAS-based studies
have experienced exponential growth, providing significant insights into our understanding
of the genetic underpinnings of diseases100,101.
To date, GWAS Studies have provided strong evidence for associations between genetic
variants and adiposity102-104 as well as inflammatory markers105-109, indicating the potential
complexity and variability of the underlying biological networks that mediate phenotypic
expression, either directly or in tandem with other factors.
3.1. Genetic overlaps between adiposity and inflammation
With the increased availability of GWAS summary results, a number of genomic regions
that were originally reported in association with obesity were later found to be similarly
associated with inflammatory traits. Evidence for such intersections has also been reported
for asthma and obesity110. In an experimental study, high levels of inflammatory markers
were observed in mice carrying genes that harbored alleles associated with increased
obesity risk111. Concurrent inflammatory effects were also reported in studies where the
expression levels of adipose tissue genes were regulated112,113. More specifically, single
nucleotide variants (SNPs) located in LRRF1P1106, FTO114,115, AdipoQ116, CSN1S1117,
FDFT1, and PCCB107 were suggested to be associated with both inflammatory markers
and obesity traits. The reverse was also observed, with genes including IL6, which encodes
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an inflammatory cytokine, found to affect energy balance118 and TNF interacting with
adiposity119.
In addition, the phenotypic synergy between adiposity and inflammatory traits, including
the expression of CRP120, interleukins120, and other cytokines121, has been consistently
observed. This phenotypic synergy provides ample evidence for the existence of
overlapping functional pathways that underly both domains and are likely to be affected
by genetic variants. Termed pleiotropic variants in the scientific literature122, these multieffect variants could help explain the underlying mechanisms that result in correlated
phenotypic expression. The finding that seemingly distinct but co-expressed phenotypes
may share genetic pathways highlights the relevance of pleiotropy in understanding these
complex traits123.
3.2. Study of pleiotropic variants offers novel biologic insight
Pleiotropic variants are known to be pervasive124 and have the potential to do the
following. (1) Clarify the molecular functions of phenotype-associated loci and identify
common functional pathways between multiple phenotypes124. (2) Inform the classification
and treatment of patients. Although current treatment strategies combine therapies directed
at distinct cardiovascular disease risk factors, an alternative approach, which may
potentially be informed by the investigation of pleiotropy, is the identification and targeting
of mechanistic “common denominators.” Similarly, drugs that are developed to treat a
specific disease phenotype could be repurposed if a common therapeutic target was
identified. (3) Prioritize variants for functional follow-up. The vast majority of GWASidentified variants are not causal but, instead, are correlated with true causals variant
through linkage disequilibrium (LD)125,126. However, distinguishing associations that
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represent shared effects for a single variant from among multiple independent variants that
co-localize is crucial for interpretations of mechanistic models127. (4) Increase the
statistical power of novel locus discovery128. Inconsistencies between estimated and
explained heritability129 and substantial proportions of variance can be explained when
considering all GWAS SNPs130,131. The number of GWAS-identified novel loci continues
to increase as sample sizes increase128, which suggests that multiple loci remain
unidentified. Previous studies by several research groups132,133 have demonstrated how
harnessing pleiotropy can increase the statistical power of novel locus discovery.
4. Gaps in adiposity–inflammation pleiotropy research
4.1. Inadequate number of studies
Despite their potential for illuminating the origin of complex traits, including
inflammation and adiposity, the exploration of pleiotropic variants has been limited, and
the underlying mechanisms associated with these SNPs remain largely uncharacterized.
The studies referenced in the previous section constitute a substantial proportion of the
existing literature on adiposity–inflammation pleiotropy, which highlights the need to
perform additional research and in combination with functional studies.
4.2. Methodological challenges
In most instances, whether overlaps in the GWAS-identified loci reflects mediated
pleiotropy (i.e., an SNP influences adiposity, which, in turn, affects inflammation)127 or
represents biological pleiotropy, with distinct SNP effects on each phenotype remain
unresolved. Restricting attention to genome-wide significant or even suggestive SNPs will
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typically underestimate the extent of pleiotropy, as SNPs with more modest effects will be
excluded134.
Interrogating pleiotropy by comparing phenotype-specific SNP lists can often fail to
distinguish between SNPs that represent biological pleiotropy from SNPs that co-localize
due to (1) spurious associations, which may reflect ascertainment bias where SNP
associates with co-occuring trait135, phenotypic misclassification136, allelic structure, or
shared controls137; or (2) reflect ambiguity in mapping the true underlying causal variant,
particularly with non-coding variants that have tissue specific effects138.
4.3. Limited inference
Methodological issues and the inadequacy of current pleiotropy research are not the only
factors hindering further exploration and functional characterization of multi-trait
associated variants. Most existing GWAS and pleiotropic studies have been performed on
largely European ancestry populations. The confinement of investigations to specific
groups139,140 can create a biased view of human variation and hinders the translation of
genetic associations into clinical and public health applications that are relevant for all
populations141. In addition, these studies fail to leverage the genetic architecture of
racial/ethnic minority populations and miss opportunities to pinpoint unique variant-gene
combinations.
The conclusions formed from existing studies may warrant limited generalization given
the differential distribution of inflammatory markers associated with comparative adiposity
configurations142, patterns of fat accumulation143,144, and the prevalence of cardiometabolic
abnormalities in minority groups, such as Hispanics/Latinos145. These differences have
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been persistently observed in various settings; for instance, in the multiethnic Insulin
Resistance Atherosclerosis Study (IRAS) cohort, Hispanic participants were found to
present significantly higher concentrations of circulatory CRP and plasminogen activator
inhibitor-1 (PAI-1) in adiposity adjusted analyses146. Ethnic disparities were also identified
for adipokine levels between participants in the Study of Women’s Health Across the
Nation (SWAN), even after accounting for adiposity measures142.
Given the cross-phenotypic effects of genetic loci associated with adiposity147, the
ancestry-specific genetic architecture may underpin the disparities observed in adiposityassociated cardiometabolic risk factors and associations between ethnic groups148.
Therefore, the investigation of genetic underpinnings is critical for an understanding of
the mechanisms that result in disparities in cardiovascular risk factors between
Hispanic/Latino populations and other populations. The handful of existing assessments
involving minorities have limited inferential utility, largely due to smaller sample sizes,
which have unsurprisingly resulted in contrasting conclusions149,150.
Uncovering the genetic underpinnings of ancestry-specific inflammatory pathways that
link central adiposity with the metabolic abnormalities that are considered precursors to
deleterious cardiovascular outcomes is essential in this population. A genome-wide,
systematic, and comprehensive evaluation of pleiotropic genes that overlap between
adiposity and inflammation phenotypes in Hispanic/Latino populations is necessary to
identify these genetic effects.
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4.4. Adiposity–inflammation pleiotropy study in Hispanics/Latinos
The tri-admixed nature of Hispanic/Latinos captures genetic variations from Amerindian,
African, and EU populations151, and facilitates the detection of variants that are
infrequent/monomorphic

in

more

homogeneous

populations,

as

demonstrated

previously152,153.
Hispanics/Latinos also present opportunities for estimating causal probabilities for
GWAS inferenced variants (fine-mapping)154, due to shorter shared haplotypes compared
with EU populations155. Fine-mapping is even more powerful in the context of data from
non-European ancestry populations156, greatly reducing the number of SNPs identified for
functional evaluations157,158.
The provision of new genetic and molecular insights into such complex traits in this era
of precision medicine is intended for clinical utility and the development of effective
preventive strategies designed to improve the cardiovascular health of Hispanics and, by
extension, all ethnic groups through the reduction of associated metabolic risk factors.
5. Study Rational
Assuming that adiposity and inflammation are interrelated manifestations of biological
mechanisms, the identification and study of the genetic variants that underpin such
mechanisms can enable the examination of phenotypic classifications, the repurposing of
pharmaceutical interventions, and ultimately, cardiovascular disease prevention. The
conceptual framework for the study is graphically illustrated in Figure 1.5.
The selection of a Hispanic population with unique, tri-admixed genetics will highlight
functional variants and their associated pathways at the molecular level.
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6. Aim of the Study Project
We aim to characterize the adiposity- and inflammation-associated genetic pleiotropy
underpinning cardiovascular risk factors in Hispanic Americans by using observations
from the Cameron County Hispanic Cohort (CCHC). By utilizing phenotypic and
genotypic data, combined with advanced statistical approaches, SNPs that are significantly
associated with adiposity and inflammatory traits will be explored, fine-mapped to identify
functional variants, and sorted to distinguish biological and pleiotropic variants.
The specific aims of this dissertation are:
1) Identify loci with potential evidence for pleiotropy across inflammation, overall
obesity, and central adiposity domains in a Hispanic/Latino population.
By employing measures of overall obesity (BMI), central obesity (waist to hip ratio, waist
circumference), and inflammatory traits (CRP, Fibrinogen, IL-6, and IL-8 levels) obtained
from blood samples159, the study intends to perform the following:
a. Estimate genome-wide univariate associations between approximately 10 million
SNPs and Aim 1a phenotypes.
b. Apply the adaptive sum of powered score (aSPU) test160 to the Aim 1a summary
statistics to identify potentially pleiotropic loci across phenotypic domains.
2) Leverage allelic associations and variants’ functionalities to prioritize SNPs for
in-depth statistical and experimental interrogation.
a. Using PAINTOR161 and FINEMAP162 to conduct fine-mapping on the loci identified
in Aim 1b, prioritize SNP candidates for additional statistical and functional evaluation.
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3) Distinguish SNPs with evidence for biological pleiotropy.
a. Application of pathway analysis to differentiate Aim-2 prioritized SNPs with evidence
of biological pleiotropy (e.g., variants that influence several independent phenotypes) from
mediated pleiotropy.
The specific hypotheses are that: (1) genome-wide assessment will highlight loci that
potentially affect multiple inflammatory- and adiposity-associated phenotypes (Aim 1). (2)
At these possibly pleiotropic loci, fine-mapping informed by population structure and
functionality will pinpoint functional SNP candidates (Aim 2). (3) Some of these
candidates will illustrate evidence of biological pleiotropy (Aim 3).
By considering obesity and inflammation to be interrelated manifestations of biological
mechanisms, rather than in isolation, this proposal will pave the way towards gene and
functional variant identification, enabling research examining etiology-based phenotype
classification, drug repurposing, and, ultimately, cardiovascular disease prevention.
A Hispanic-Latino population was intentionally selected as a population with a high
burden of disease, and that is often underrepresented in genomic studies, which ensures
that our proposed study is innovative, particularly as next-generation sequencing, precision
medicine, and direct-to-consumer genetic testing become more commonplace, in the
context of an increasingly diverse population163.
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7. Tables and Figures
Figure 1.1. Obesity increases extracellular matrix levels within the kidney and may cause
medullary compression, altering the intrarenal mechanical forces. This structural change
increases reabsorption of sodium in the Henle Loop and conversely reduce sodium levels
in Macula denasa. The latter event would trigger renin-angiotensin system and increases
glomerular fiteration rate and renal blood flood, resulting in elevated extracellular fluid
volume, increased hemodynamic load and ultimately hypertension which is a precursor to
major cardiovascular adversities (Hall, J.E., 1997) .
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Figure 1.2. Adipocytes expand and replicate to store positive energy balance in the shape
of lipids. The rapid or sustained accumulation of lipids can disrupt the differentiation of
preadipocytes and accelerating the formation of larger, dysfunctional adipocytes that have
altered hormonal and inflammatory profile (Van Gaal et al., 2006).

Figure 1.3. Hypertrophied adipocytes upregulate production of proinfommatory cytokines,
including IL-6, that are key drivers of C-reactive protein (CRP) production in the liver
(through direct liver access via the portal system. Within this inflammatory milieu,
increased concentrations of macrophages admixed with lipolytic and apoptotic adipocytes
promote positive feedback loops, resulting in the amplification of adverse metabolic and
inflammatory actions (Van Gaal et al., 2006).
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Figure 1.4. Functional ovrelapp and feedback loop has been suggested where weight gain
causes inflammation, resulting in metabolic/structural alterations that induce further fat
accumulation
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Figure 1.5. The conceptual framework for the adiposity-inflammation pleiotropy study.
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METHODS
This chapters present information on study population, quality control procedures, and
statistical approaches proposed for the data analysis. The review highlights the study
setting and the recruitment process. Discussions entail descriptive analysis of genetic and
phenotypic observations, variable selection, genetic data quality assessment and
imputation, exclusion/inclusion criteria and outlier examinations. Mathematical summaries
of the proposed statistical methods are provided in the latter part of the chapter.
1. Study Setting
Cameron County, in the state of Texas, is the southernmost county in the US. According
to a recent Population and Housing Units Estimates report, provided by the US Census
Bureau (in 2020) , the total population of the county is 423,163 individuals (census.gov),
with the large majority (approximately 88%) self-identifying as Hispanic or Latino.
The county harbors a high percentage of residents who were born in Mexico164, are
economically classified as low-income, and have lower educational attainment than the
national average164. Based on data from 2004-2015 period, only one-third of the individuals
in this county were covered by any type of health insurance program165. The prevalence of
obesity (57%), prediabetes (32%), diabetes (28.7%), hypertension (31.0%), and
hypercholesterolemia (50.1%) among this population suggests high susceptibility to
cardiovascular diseases and chronic inflammatory diseases166,167.

23

1.1. Conception
The CCHC study started in 2004 and continually developed and expanded ever since.
This study is intended to be a “Framingham-like” open enrollment observational cohort
consisting of a Hispanic population, providing a setting for the exploration of a variety of
health-related topics.
This initiative is primarily funded by the National Institute for Minority Health
Disparities (NIMHD). Current research involving this cohort includes the study of diabetes
risk, cardiovascular disease, peripheral artery disease, liver disease, cancers (liver/breast),
mental health, intervention studies, genomics, immunology, imaging/elastography, clinical
trials, and economics.
1.2. Recruitment process
Recruitment is ongoing, and the number of participants is now approximately 5,000
individuals; Medical examinations and interviews are performed at Clinical Research Units
(CRUs) in both Brownsville and Laredo, Texas. The first round of recruitment included
2,000 participants and was performed between 2004–2007.
Although most participants have been adults, a small pediatric group (8-17 years old)
was also enrolled in the study. Regular follow-up visits, performed every 5–10 years, are
planned for participants recruited at baseline to allow for longitudinal data collection, using
nested study designs, and the implementation of clinical trials.
Using a 2-stage, stratified sampling design, census tracts were classified into 4 strata
according to income level. Targeted sampling was performed on the first (lowest) and third
socioeconomic strata. From 42 clusters in the lower socioeconomic stratum, 11 tracts were
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selected for random sampling; similarly, 11 tracts were selected from among the 39 clusters
in the higher socioeconomic stratum164. The highest stratum was omitted because it
contained predominantly “winter Texans,” who were primarily retired visitors from the
northern United States and Canada and were less likely to be Hispanic.
All households within a selected census block were invited to participate in the study.
Overall, 71% of approached households elected to participate, with more participants from
the lower SES stratum than from the upper stratum (78% vs. 63%); then, one person from
each household was randomly recruited for the study. The recruitment process is currently
in the second stage and is ongoing. Recruiters are from the local population and are
bilingual and bicultural. Each randomly selected household was visited at least 5 times.
The institutional review boards at the University of Texas Health Science Center and the
University of Texas at Brownsville reviewed and approved the protocol. They also
approved the informed consent forms, which included permission to collect and store deidentified data and specimens for this and other studies.
2. Data Collection
Those who agreed to participate were then invited to visit a CRU for examinations. All
questionnaires and explanations were scripted in both English and Spanish, and
participants were not asked to fill out any forms. Questionnaires and examinations were
conducted by nurses and field workers, who were trained in good clinical practices, in
accordance with the National Institutes of Health requirements.
2.1. Anthropometric measures
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The weights of the participants were measured with their shoes removed and recorded to
the nearest 0.2 kg using a Seca digital scale (Birmingham, UK). Standing height (cm) was
measured measured and recorded to the nearest 0.2 cm using a Perspective Enterprises
stadiometer (Portage, MI, USA) and weight (kg). BMI was measured by dividing the body
weight over the square of the height in meters (m2); waist circumference (visceral
adiposity) was measured to the nearest 0.2 cm at the level of the umbilicus, with
participants in a standing position and breathing normally164. All measurements were
performed twice, and the mean value was recorded in the dataset.
2.2. Inflammation biomarkers
Participants were asked to fast for at least 10 hours overnight before their visit to the
CRU, which was located centrally at Valley Baptist Medical Center. After confirming the
duration of their fast, blood samples were obtained for subsequent laboratory
measurements and DNA sequencing; participants who had not fasted were rescheduled164.
Specimens were aliquoted and frozen at −80°C. CRP levels were analyzed at a Clinical
Laboratory Improvement Amendment (CLIA)-certified laboratory. IL-6 and IL-8 which
are markers of chronic, low-grade inflammation, were measured using a multiplex enzymelinked immunosorbent assay (ELISA, Milliplex Map, Millipore, CA, USA) and read in a
Luminex 200 system (Luminex Corp., Austin TX).
2.3. Genetic measurements
Genetic measurements were completed at the Vanderbilt University Medical Center
genotyping core facility, VANTAGE. Genotyping was performed using a MEGA-Ex
panel, which included >2 M variants. MEGA also incorporates 400K low-frequency and
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rare disruptive variants that were originally derived from a pan-ethnic panel of 40K wholeexome sequenced (WES) individuals and a heavily curated catalog of > 40K clinical
variants. Measurements were recorded in binary PLINK format 168.
3. Exploratory Analysis of Genetic Measurements and Quality Control
Out of 2,038,233 total genotyped variants, 1,842,794 single-nucleotide polymorphisms
(SNPs) passed initial lab control, whereas the remainder did not perform consistently and
were, therefore, dropped from the initial data set.
3.1. Pattern of missingness
Allelic frequency distribution showed that out of 1,842,794 total variants, slightly greater
than 50% were classified as rare variants, which are defined as SNPs with minor allele
frequencies (MAFs) of < 1% (Figure 2.1). Next, the per variant missingness was assessed
(Figure 2.2). Although a sizeable proportion of variants (approximately 24%) had a
maximum of 1% missingness, the proportion of variants with missingness equal to or
exceeding 5% were negligible (approximately 5%).
Next, per sample missingness were examined. The initial exploration of samples from
the first batch (available at the time of assessment) illustrated that approximately 3% of
samples were missing 10% of genotyped variants or less, and nearly 4% of samples had a
5% missingness or less.
Finally, the pattern of per sample missingness compared to the distribution of autosomal
heterozygosity was examined (Figure 2.3). Using a threshold equal to the median ± 3 × the
interquartile range, pattern missingness vs. autosomal heterozygosity was assessed, and no
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sample was found to be outside of the threshold range. Larger than expected heterozygosity
can indicate the possible contamination of DNA samples.
3.2. Sex mismatch
To determine genetic sex, we assessed the inbreeding coefficient for the X-chromosome
or the F coefficient ratio169, which represents the probability that a person receives genetic
markers on the X-chromosome from a single ancestor.
Because males have only one X-chromosome (received from the mother), the coefficient
is defined to be 1, regardless of inbreeding. For females, the X-chromosome kinship
coefficient is either 0 (completely outbred) or close to 0, if any degree of kinship is
identified between the parents.
Generally, an F coefficient value < 0.2 is considered to be genetically female, whereas a
value > 0.8 is considered to be male. The distribution coefficients generally correlated with
the pedigree sex (Figure 2.4), with some mismatches. autosomal allelic heterozygosity
compared with X-chromosome (sex) heterozygosity was also assessed (Figure 2.5); results
were similar to the F coefficient distribution and similarly included some mismatches
between genetic vs. pedigree sex.
3.3. Genetic outliers
CCHC genetic observations were merged with 925 samples from the 1000 Genomes
(1000G) project population to assess the alignment of the study participants against
reference ancestries using the smartpca tool from the Eigensoft package. A plot of the first
2 principal components (PCs, Figure 2.6a) suggested a few outliers with different
ancestries compared with the rest of the samples; however, these samples did not
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consistently separate from the rest of the samples when the third PC was considered (Figure
2.6b and c).
3.4. Hardy-Weinberg Equilibrium
Determining whether genotypic frequencies are in Hardy-Weinberg Equilibrium (HWE)
is an important step that must be performed during the quality analysis of genotyped
variants. The HWE states that the allelic frequencies of autosomal genes in a population
remain unchanged throughout generations in the absence of disruptive forces, such as
assortative mating, mutation, and migration. However, a departure from HWE is most
likely indicative of potential genotyping errors or population stratification. Yet, given that
the cohort under study is a recently admixed population, only extreme deviation from HWE
was considered. A negligible number of variants were found outside of the significant
thresholds for HWE (< 10−6, < 10-20, <10−50, Figure 2.7).
3.5. Duplicated samples and variants
After analysis with Kinship-based Inference for Gwas (KING)170, 76 pairs of samples
were found to have > 80% genetic concordance with each other. A similar number of pairs
were also found during the pedigree reconstruction process using PRIMUS171 (Figure 2.8).
Additionally, approximately 50K variants were also found to be duplicated.
3.6. Quality control process
Based on empirical observations from prior steps and the template proposed for
performing genome-wide association studies (GWAS)172, the following quality control
steps were performed:

29

a) removing duplicated variants and indels (insertions/deletions).
b) removing variants with low MAF (< 1%).
c) excluding samples with more than 5% missingness and variants with greater than
5% missingness (among all samples).
d) excluding samples with genetic vs. pedigree mismatch (F > 0.3 for females).
e) removing samples that fall outside of the heterozygosity threshold or or HWE
significance level (p-value < 1−10), and
f) removing variants with either allelic or stand mismatch compared against the
reference 1000G panel (this step was only completed for dataset used for imputation
with 1000G).
In Table 2.1, the rows represent the temporal sequence for the process. All the steps were
completed using the PLINK package.
4. Principal Component Analyses
In recent years principal component analysis (PCA) has been the most widely adopted
approach for both ancestry inference and the correction of population stratification in
genomic studies that utilize high-density SNP genotyping data173. To calculate PCA,
filtered data were used that were previously assessed for quality control standards (as
discussed above) and further subseted these data to include only common variants, with
MAF > 5% (approximately 117,000 SNPs)The selection of common variants can improve
ancestry inferencing because these variants are more likely to be observed in reference
populations outside of the study.
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Using this common variant subset, PCs were calculated using the packages GENESIS174
(for PCAir) and PRIMUS171 (PCA). The primary difference between PCAir and PCA is
that PCAir adjusts for pairwise kinship. The GENESIS method utilizes genomic
observations and an efficient algorithm175 to identify a diverse subset of unrelated samples,
which are representative of all ancestries in the data. GENESIS uses pairwise relatedness
and ancestry divergence measurements on genotyped variants from the autosomal
chromosomes and separates the dataset into an ancestry representative subset, u, of
unrelated individuals from the total sample, N. PC estimates obtained from the analysis of
a subset u would then be used to predict PCs in the set of related individuals, R, based on
genetic similarities175. Samples from 1000G were used as the ancestry references (N =
2,504).
Procedurally, PCs were first calculated using a combined set of unrelated CCHC
individuals and reference samples. The threshold for relatedness was set to a 3rd-degree
relatives, which equates to a first cousin or more distant relative. A slight difference in the
number of unrelated individuals was calculated by PRIMUS vs. GENESIS (2,282 vs. 2,253)
due to differences in their respective computational algorithms. Subsequently, PCs were
calculated during the first phase and were then projected over the subset of related samples
(Figure 2.9).
A sizable majority of CCHC individuals clustered with predominantly Mexican
populations, and smaller sets clustered with other ancestry groups (Figures 2.9). The
parallel plot of the first 10 PCs also suggested the primacy of Mexican ancestry among the
study participants (AMR group in Figure 2.10).
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The analysis of explained variance by PC (Figure 2.11) suggested that a negligible
proportion of variations in the data is captured by PCs beyond the 3rd PC. No practical
difference was observed between the PRIMUS-calculated PCA and PCAir (Figure 2.12);
therefore, PRIMUS-derived PCs were selected to ensure consistency with other research
studies using the same cohort.
5. Imputation
5.1. Pre-imputation quality control
Using McCarthy group tools (well.ox.ac.uk/~wrayner/tools), genotyped variants
underwent further quality control assessments. Steps included strand update (top strand),
position check, and the assignment of reference/alternative allele assignments for
genotyped PLINK files. The following categories of variants were excluded from the set:
i) A/T and G/C SNPs if MAF > 0.4.
ii) SNPs with differing alleles (relative to the reference genome), and
iii) SNPs with > 0.2 allele frequency difference (compared to the reference genome).
5.2. Imputation panels
A cleaned dataset was loaded into the Michigan Imputation Server176 for imputation
using a 1000G Phase 3 panel and a Trans-Omics for Precision Medicine (TOPMed) freeze
8 panel (imputation.biodatacatalyst.nhlbi.nih.gov). The advantages of the 1000G panel
include well-characterized reference ancestry groups, along 26 clusters and from all
continents and wider adoption in genetic studies, which would facilitate the replication and
meta-analysis of different studies using the same set of variants.
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TOPMed (nhlbiwgs.org), in contrast, is a consortium of over 30 different study cohorts.
Compared with 1000G, the latest freeze 8 reference panel was inferenced from the deep
sequencing of 186K individuals, which represents a substantial improvement in the
number of available variants for imputations and increased diversity of ancestry groups.
Currently, this freeze includes 811M SNPs and 66M short indel variants. The availability
of larger numbers of SNPs would greatly facilitate genetic studies that involve rare or
ancestry specific variants. However, TOPMed is a work in progress and is not yet as
widely adopted as 1000G.
5.3. Imputation procedure
With both 1000G and TOPMed servers, imputations were completed with the
Minimac4177 imputation platform. The mean imputation accuracy was set to 10%. For
genotype phasing, where each allele is assigned to its proper pair of (paternal or maternal)
chromosomes (for haplotypic referencing), the Eagle phasing algorithm178 was utilized.
During the TOPMed imputation run, all populations were selected as the parameters for
ancestry reference.
The results and the number of variants imputed with TOPMed for each chromosome are
presented in Table 2.2. An average of approximately 92% alignment between the reference
panel and the genotyped set was achieved. Additionally, the results from the TOPMed
panel were converted to a newer genome reference consortium human build 38
(GRChr38)179.
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5.4. Post-imputation quality control
Variants with rare MAF (< 1%) and poor imputation quality (< 40%) or monomorphic
(i.e., all individuals having the same genotype at a given site) within the study population
were excluded from this analysis. After the completion of the recommended quality control
steps, approximately 9 million SNPs remained, which were used for subsequent analyses.
6. Phenotypes
BMI was selected as the measure for overall adiposity, and WHR and WC were selected
as reliable indicators of central obesity and visceral adiposity, respectively; all three
measures are significantly correlated with inflammatory markers and have been widely
adopted in GWAS research on adiposity traits. For inflammation, phenotypes, including
CRP, IL6, IL8, and fibrinogen, were included in the assessment (Table 2.3). Exploratory
analyses of the target traits showed skewness in the distributions of inflammatory markers,
which was suggestive of extreme values at the left tails, although a few high values were
also observed for BMI and WHR (Figure 2.13). The data included measurements taken at
both visits 1 and 2.
6.1. Covariates
For GWAS analysis, covariates including age (year), sex and BMI were considered. For
pathway analysis, age, sex, physical exercise (binary, 150 min of moderate to viborous
activity/week), alcohol consumption (Ounce/week), current smoking status (binary) and
homeostatic insulin resistance (HOMA-IR, uIU/mL) were used. Covariates used for
pathway analysis were similarly taken from the exams where the primary phenotypes were
selected.
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6.2. Inclusion/exclusion criteria
The study population was restricted to individuals whose genetic data were available
(3,313 out of 4,933). All participants under the age of 15 were excluded from the study
because notable differences exist between genes that affect childhood vs. adulthood
obesity180. Prior assessments in larger settings also suggested sexually dimorphic
anthropometric variants in regard to central obesity181; therefore, both WHR and WC traits
were stratified by sex. Finally, the log-transformed distributions of traits were assessed.
For the IL-6 and IL8 phenotype, the empirical distribution suggested a proportion of
observations with the same value (0.64 pg/dL), and this pattern was often observed with
measurements taken before January 2010. This value is unlikely to have been the detection
threshold for the assay because values smaller than 0.64 were identified. Whether some
portion of the values were rounded as a standard reporting practice could not be
determined. To minimize bias in the results, the last non-missing observation for each trait
in each sample was selected for GWSA analysis (Table 2.4).
6.3. Examination of phenotypic outliers
A considerable number of extreme observations were identified at both tails (Figure 2.13,
empirical distributions; Figure 2.14, log-transformed distributions). Although outliers
could introduce noise or induce false-positive associations in genetic tests, aggressive
filtration can reduce sample sizes and inversely affect power; therefore, a delicate balance
is necessary. To address this issue, two comparative methods were utilized:
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6.4. The minimalistic approach
Using the minimalistic approach, both biological plausibility and empirical distributions
(both raw and log-transformed) were used as criteria for setting outlier cut points. For
anthropometric traits, almost all of the observations were in ranges that were biologically
plausible, even if clinically abnormal. Therefore, only a few extreme cases that were
considerably detached from the rest of the distributions at each tail were excluded.
For CRP, clinical studies have shown that concentration levels above 350 (mg/L) are
indicative of underlying severe acute inflammation182, whereas levels ranging from 10–
100 (mg/L) could either indicate active inflammation or be a high normal. Given the
empirical distribution and clinical criteria, a few observations above 200 (mg/L) were
excluded.
For IL6, the upper range of measurement can be as high as 1000 (pg/dL), especially in
individuals with underlying conditions (e.g., infection, cancer, chronic diseases). However,
we used both empirical distribution and the reported literature to determine a cut-off point
of 100 (pg/dL) as the threshold for outliers, as observations above this level are generally
considered to be abnormal and are less likely to be observed in individuals without acute
inflammation183,184.
For IL8, levels as extreme as 10,000 (pg/dL) have been reported in severely ill patients185.
Based on the empirical distribution and the highest ranges known for non-acute cases, the
threshold was set to 80 (pg/dL)186,187. For all traits, extremely low measurements (observed
in the log-transformed distributions, Figure 15) were also excluded. After the filtration of
outliers, the remaining measurements were log-transformed and rank-normalized.
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6.5. Hybrid approach
Although the minimalistic approach excluded extremes, the dataset continued to include
values that were otherwise abnormally high or low; therefore, the possibility of severe or
acute underlying diseases being present at the time of measurement could not be excluded.
In such scenarios, data is customarily rank-normalized to minimize the likelihood of bias
in the results; however, this process can induce additional problems, such as the loss of
statistical power188. Therefore, a more conservative outlier examination was deemed
necessary, particularly for inflammatory traits.
First, the distribution of inflammatory markers in similar Hispanic ancestry populations
was reviewed in the literature (Table 2.5), which provided inferences for setting standard
deviation-based cut-off points for each trait. Subsequently, the data were log-transformed,
and the values outside of the proposed cut-off points were then set to missing. Descriptive
distributions of the study phenotypes used during the hybrid filtration approach are
presented in Table 2.6.
Lastly, outliers were examined to ensure that no specific pattern could be observed.
6.6. Selection of the phenotype set
No discernible difference was observed for either phenotype set after the conclusion of
the GWAS tests. Therefore, the results from the hybrid assessment process were selected
for subsequent analyses.
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7. Statistical Approach
7.1. Genome-wide association test
Generalized linear models are now the primary statistical tools used during association
analyses in various scientific fields189, including biology. Assuming that the subjects are
independent, the linear association between the outcome (phenotype) and predictor (SNP
variant) can be written as 𝑀1: 𝑔(𝐸(𝑌)) = 𝑋𝛼 + 𝐺𝛽, where 𝑌 is a vector for continuous or
binary phenotype data, 𝑔 is a link function, 𝑋 denotes confounders, and 𝐺 is the SNP
dosage.
However, given the study setting, in which a sizeable proportion of the individuals have
kinship relationships with each other, a generalized linear mixed model (GLMM) would
be more appropriate to allow for family structure adjustments, beyond the ancestry PCs
that account for most distant relatedness and ethnic variations. Hence, a mixed model was
implemented in the GENESIS package190 for use during GWAS tests.
GENESIS fits linear mixed models for quantitative phenotypes and penalized-quasi
likelihood for binary (or count) traits. In comparison with other packages that use the
Likelihood Ratio or Wald tests

191-193

, GENESIS uses the Lagrange-Multiplier (score)194

test. A distinguishing feature of score-based tests is that only the null model must be
specified to make statistical inference; thus, this type of model is computationally faster
than the other two types, for which more complicated models must be fitted.
The package uses a reduced maximum likelihood (REML) algorithm195, a special form
of maximum likelihood estimation, in which the degrees of freedom are used to estimate
fixed effects while calculating variance components. Compared with the general maximum
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likelihood method, REML operates on linear combinations of observations, chosen such
that those combinations are invariant to the values of fixed-effect parameters.
Relatedness due to familial relationships is accounted for by including a random effect
term with a covariance matrix proportional to the genetic relationship matrix (GRM) or
kinship matrix 𝐾. Specifically, the GLMM assumes that the variance matrix for the
phenotype 𝑌 has the form 𝑉1: 𝑉𝑎𝑟(𝑌) = 𝜎 2 𝐼 + 𝛾 2 𝐾, where 𝐼 is the identity matrix. In a
single SNP analysis, the computing time was greatly reduced by estimating 𝜎 2 and 𝛾 2 from
the null model 𝑀0: 𝑔(𝐸(𝑌)) = 𝑋𝛼 and then using these estimates in a score test of 𝛽 = 0
in 𝑀1.
For the family structure effect, the GENESIS package uses PC-Relate196. Briefly, PCRelate is a PC-based approach for the estimation of commonly used measures of recent
genetic relatedness, such as kinship coefficients and identity by descent (IBD), which share
probabilities in samples with population structures, admixture, and HWE departures.
PC-Relate is essentially a hypothesis (model)-free approach for inferring recent kinship
because it does not require prior estimates of individual ancestry and population-specific
allele frequencies, IBD-sharing likelihood models, or the specification of a population
genetic model. It uses PCs calculated from genomic data to partition genetic correlations
among individuals into two separate groups based on the sharing of recent or more distant
common ancestry196.
7.2. Pleiotropy assessment
Various pleiotropy methods have recently been proposed197 that take advantage of the
increased availability of summary statistics from trait-specific GWAS. Most of these
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methods offer superior statistical power compared with multivariate analysis198. Because
the GWAS results in this study were based on score tests, the adaptive Sum of Powered
Scores test (aSPU), which itself is essentially a score-based test, refined for multi-trait
association testing199, was used for pleiotropy assessments.
Briefly, suppose 𝑈 = (𝑈1 … 𝑈𝑘 )𝑇 to be the score vector for a set of k trait-SNPs to be
tested with the H0: β = 0. The score test is: 𝑇𝑆𝑐𝑜 = 𝑈 𝑇 𝑉 −1 𝑈, which is equivalent to an
asymptomatic Wald test with k degrees of freedom. The popular single-variant test for
correlated traits is the univariate minimum P (UminP) method, which tests every single
variant, one-by-one, and selects the minimum of their p-values200.
Pan et al. showed that the corresponding multi-trait UminP for score-based tests is
𝑇𝑈𝑚𝑖𝑛𝑃 = max 𝑈𝑗2 /𝑉𝑗𝑗 201, where Uj is the element of U, and V is the (j,j) diagonal element
𝑗=1,…,𝑘

̂ (𝑈). However, when the number of traits increases, the test loses power.
of the 𝑉 = 𝐶𝑜𝑣
To address this issue, the sum of score tests was proposed202: 𝑇𝑆𝑢𝑚 = ∑𝑘𝑗=1 𝑈𝑗 .
This test may also be ineffective when the direction of effects across traits differs. One
solution was the sum of squared score (SSU) test202: 𝑇𝑆𝑆𝑈 = 𝑈 𝑇 𝑈 = ∑𝑘𝑗=1 𝑈𝑗2 , which was
later scaled to a more generalized test that can be adapted for different scenarios 203:
𝛾

𝑇𝑆𝑃𝑈(𝛾) = ∑𝑝𝑗=1 𝑈𝑗 , where gamma is the power parameter. Note that when the gamma
parameter

approaches

infinity203,

𝛾

𝑇𝑆𝑃𝑈(𝛾) ∝ (∑𝑝𝑗=1|𝑈𝑗 | ) 1/𝛾 → max|𝑈𝑗 | = 𝑇𝑆𝑃𝑈(∞) ,
𝑗

which is similar to the UminP test. Each gamma value may yield a higher power under
certain scenarios.
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However, because these scenarios cannot be known in advance, an adaptive (aSPU)
approach is necessary to maximize the power of a given set of gamma values; hence204:
𝑇𝑎𝑆𝑃𝑈 = min 𝑃𝑆𝑃𝑈(𝛾) , where 𝑃𝑆𝑃∞𝑈(𝛾) is the pleiotropic p-value of the test and Γ contains
𝛾∈Г

a set of suggested gamma (i.e. 1,2,3…∞) values, of which at least one value may maximize
the detection power.
7.3. Fine-mapping
Although GWAS or pleiotropy analysis can provide crucial insights into the genetic
underpinnings of phenotypes, these analyses do not necessarily indicate causality. Due to
linkage disequilibrium (LD) between SNPs or coverage quality of genotyping panels (SNP
tagging)205, variants with the lowest p-values may not be phenotype-affecting SNPs.
Fine-mapping is a statistical analysis approach that can be used to assign a causal
probability to GWAS-inferenced variants. In this study, two complementary methods were
utilized for fine-mapping loci with suggestive evidence for multi-trait associations after
pleiotropic analysis.
7.3.1.

PAINTOR

The PAINTOR (Probabilistic Annotation INTegratOR) approach takes advantage of both
the LD structure and functional annotation. In association analysis for continuous traits,
values are marginally regressed on each variant, and the corresponding Z-score (𝛽̂ /𝑠𝑒(𝛽̂ ))
is obtained.
Assuming that 𝑍𝑗 is the vector of the [pleiotropic] Z-score in the 𝑗 𝑡ℎ locus (1 ≤ 𝑗 ≤ 𝐿)
of the size 𝑁𝑗 (i.e., total number of SNPs in the locus); Σ𝑗 is the corresponding SNP pairwise
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pearson correlation coefficient for the locus 𝑗 (i.e., LD matrix), derived from a set of
unrelated individuals with 𝐾 annotations (1 ≤ 𝑘 ≤ 𝐾) for each SNP 𝑖; 𝐴𝑖,𝑗 is a binary
vector where 𝐴𝑖,𝑗,𝑘 = 1 if the 𝑖 𝑡ℎ variant at the 𝑗 𝑡ℎ locus is part of the annotation 𝑘; 𝛾𝑘 is
the effect size of the 𝑘 𝑡ℎ annotation on the probability that a SNP is causal; 𝜆𝑖 is the vector
of non-centrality parameter ; 𝐶𝑗 is the vector of causality, where 𝐶𝑖,𝑗 = 1 if SNP 𝑖 at the
locus 𝑗 is causal; then the prior probability of the Bayes formulation is206:
𝑃(𝑍𝑗 |𝐶𝑗 ; 𝜆𝑗 ) = 𝑁(𝑍𝑗 ; Σ𝑗 (𝐶𝑗 ∘ 𝜆𝑗 ), Σ𝑗 )
𝑃(𝐶𝑗 ; 𝛾𝑘 ) = ∏ 𝑃(𝐶𝑖𝑗 ; 𝛾𝑘 ) … (1)
𝑖

𝑃(𝐶𝑖𝑗 ; 𝛾𝑘 ) = (

1
1
)𝐶𝑖𝑗 (
)1−𝐶𝑖𝑗 … (2)
1 + exp (𝛾𝑘 𝐴𝑖𝑗𝑘 )
1 + exp (−𝛾𝑘 𝐴𝑖𝑗𝑘 )

PAINTOR computes posterior probabilities of each causal configuration 𝐶𝑗 over all
possible causal configurations

206

𝑁
: 𝑄𝑗 (|𝑄𝑗 |) = ∑𝑠𝑖=0( 𝑖𝑗 ), where S is the potential causal

numbers considered for each locus 𝑗. With equaitons above, the posterior probability for
each 𝐶𝑗 is206:

𝑃(𝐶𝑗 |𝑍𝑗 ; 𝛾𝑘 , 𝜆) =

𝑃(𝑍𝑗 |𝐶𝑗 ; 𝜆𝑗 )𝑃(𝐶𝑗 ; 𝛾𝑘 )
∑𝐶𝑗∈𝑄𝑗 𝑃(𝑍𝑗 |𝐶𝑗 ; 𝜆𝑗 ) 𝑃(𝐶𝑗 ; 𝛾𝑘 )

… (3)

And the posterior probability for each SNPi,j206:
𝑃(𝐶𝑖𝑗 = 1|𝑍𝑗 ; 𝛾𝑘 , 𝜆) =

∑

𝑃(𝐶|𝑍𝑗 ; 𝛾𝑘 , 𝜆) … (4)

𝐶𝑗 ∈𝑄𝑗 ;𝐶𝑖𝑗 =1

Because posterior probabilities are calculated independently for each locus, the package
undertakes further mathematical steps that aggregate results across loci and use these
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results to update likelihood parameters, particularly 𝛾𝑘 and 𝜆, which improve posterior
probability estimates. The incorporation of functional annotation has been illustrated to
significantly improve causal estimates in prior analyses158.
7.3.2.

FINEMAP

Essentially, FINEMAP is a Bayesian approach that incorporates likelihood function,
priors, likelihood estimation, and stochastic search algorithm162. Assuming a linear model
𝑦 = 𝑋𝜆 + 𝜖, where 𝑦 is vector of mean-standardized values for a quantitative trait in n
individuals and 𝑋 is a column-standardized SNP genotype matrix of dimension 𝑛 × 𝑚, the
maximum likelihood estimate of the causal variants’ effects 𝜆 depends on 𝑋 and 𝑦 though
the SNP correlation matrix. Priors for causal variants’ effect 𝜆 is calculated via 𝑝(𝜆|𝛾) =
𝑁(𝜆|0, 𝑠𝜆2 𝜎 2 ∆𝛾 ), where 𝛾 is a binary vector, for which 𝛾𝑙 = 1 if 𝑙 is causal and 0 otherwise;
𝑠𝜆2 is assigned prior variance for causal effects in units of 𝜎 2 = 1; and ∆𝛾 is a diagonal
matrix.
The probability of each causal configuration 𝛾 is assumed as 𝑝(𝛾) = 𝑝𝑘 /(𝑚
𝑘 ) when
∑𝑚
𝑙=1 𝑙 = 𝑘. The marginal likelihood of 𝛾 is obtained by integrating the causal effects of 𝜆.
The posterior probability of any causal configuration is estimated via 𝑝(𝛾|𝑦, 𝑋) =
−1

(𝑚
𝑘 ) 𝑝𝑘 × 𝐵𝐹(𝛾: 𝑁𝑈𝐿𝐿), where 𝐵𝐹 is the Bayesian factor and 𝑘 is the number of causal
variant in that specific configuration.
Finally, this approach uses the shotgun stochastic search207 to compare various causal
configurations, with each obtained through the process discussed above, to identify those
with the highest posterior probability. FINEMAP conducts a pre-defined round of
iterations within the space of causal configuration. Each iteration is defined by deleting,
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changing, or adding a causal SNP from the prior configuration, which is referred to as
manipulative sampling from the preceding iteration.
All evaluated configurations and their posterior probabilities are saved in a list, Г∗ . The
posterior probability that SNPs in configuration 𝛾 are causal is estimated by normalizing
over the Г∗ list: 𝑝(𝛾|𝑦, 𝑋) = 𝑝∗ (𝛾|𝑦, 𝑋)/ ∑𝛾∈Г∗ 𝑝∗ (𝛾|𝑦, 𝑋), and for the particular SNP 𝑙𝑡ℎ
to be causal: 𝑝(𝛾𝑙|𝑦, 𝑋) = ∑𝛾∈Г∗ 1(𝛾𝑙 = 1) 𝑝(𝛾|𝑦, 𝑋)162. The advantages of this method
are the minimal input requirements (i.e., Z-scores, minor allele frequencies, and SNP
correlations) and the possibility of probing causal configurations with higher numbers of
causal SNPs in each locus without incurring a substantial computation penalty.
7.4. Causal pathway analysis approach
Pleiotropy does not distinguish whether an observed association between a genetic
variant and a phenotype involves direct (i.e., biologic) or indirect effects due to phenotypic
correlations with the primary trait. Mediation refers to a type of conditional analysis, in
which the total effect between the predictor and the outcome is appropriated between
several factors that contribute to the association and relies on counterfactual principles208.
Using this framework, the causal effects can be viewed as the difference between two
potential phenotypic outcomes, depending on whether an individual carries the risk alleles
or not (at the same time).
Suppose 𝑇𝑖 denotes the presence of an effective allele, which would be equal to 1 if
present and 0 otherwise; 𝑌𝑖 (𝑡) would denote the potential phenotypic outcome under allelic
presence status; then, the causal effect of the variant on the phenotype would be 𝑌𝑖 (1) −
𝑌𝑖 (0) for all values of 𝑖. However, because only one state (either 1 or 0) is observable at
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any time for each 𝑖, the focus is typically shifted toward the estimation of the average causal
effect by comparing two groups based on the randomized distribution of the effect allele,
defined as 𝐸(𝑌𝑖 (1) − 𝑌𝑖 (0))209.
Assume that the causal association between a given allele and a phenotypic outcome is
totally or partially mediated by another [correlated] factor. Let 𝑀𝑖 (𝑡) denote the potential
value of a mediator of interest for subject 𝑖 for a given allele status 𝑇𝑖 = 𝑡. Let 𝑌𝑖 (𝑡, 𝑚)
denote the potential outcome that would be observed if the allele and mediating variables
equal 𝑡 and 𝑚, respectively.
In practice, only one potential outcome is observable, and that outcome, 𝑌𝑖 , is equal to
𝑌𝑖 (𝑇𝑖 , 𝑀𝑖 (𝑇𝑖 )), where 𝑀𝑖 (𝑇𝑖 )) represents the observed value of the mediator 𝑀𝑖 . The total
effect of the allele on the outcome can be written as 𝜏𝑖 = 𝑌𝑖 (1, 𝑀𝑖 (1)) − 𝑌𝑖 (0, 𝑀𝑖 (0)). The
total effect can then be decomposed into the two components: the causal mediation effect210
𝛿𝑖 = 𝑌𝑖 (𝑡, 𝑀𝑖 (1)) − 𝑌𝑖 (𝑡, 𝑀𝑖 (0)), for the effect allele status (0,1), and direct effect 𝜁𝑖 =
𝑌𝑖 (0, 𝑀𝑖 (𝑡)) − 𝑌𝑖 (0, 𝑀𝑖 (𝑡)), for subject 𝑖 and each allele status (0,1).
For both decomposed elements, including 𝛿𝑖 and 𝜁𝑖 , because only one effect allele status
is observable, the average causal mediation effect (ACME) and the average direct (ADE)
could be estimated, as 𝐸𝛿𝑖 and 𝐸𝜁𝑖 , respectively. Now the total effect can be re-written as:
1

𝜏 = 𝐸(𝑌𝑖 (1, 𝑀𝑖 (1)) − 𝑌𝑖 (0, 𝑀𝑖 (0)) = 2 ∑𝑡=0{𝛿(𝑡) + 𝜁 (𝑡)}𝑣, and under the assumption
of no interaction, ACME and ADE sum up to the average total effect211.
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7.4.1.

Sensitivity analysis

Causal pathway sensitivity analysis proposed for this study relies on the sequential
ignorability212 assumption. The test implies that after adjustment for covariates, no
unmeasured variable confounds any of: 1) variant-mediator association (i.e. ignorability of
effect allele state)212: 𝑌𝑖 (𝑡, 𝑚), 𝑀𝑖 (𝑡)) ⊥⊥ 𝑇𝑖 |𝑋𝑖 for all 𝑡, 𝑚 = 0,1, where 𝑋𝑖 is covariate(s),
2) allele-phenotype outcome association: 𝑌𝑖 (𝑡, 𝑚) ⊥⊥ 𝑀𝑖 (𝑡))|(𝑇𝑖 = 𝑡, 𝑋𝑖 ) for all 𝑡, 𝑚 =
0,1, and 3) mediator-outcome relationships. The validity of the this mediation method
largely rely on assumption 1, regardless of whether hierarchical models are fitted to the
data or not, which is an important consideration.
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8. Tables and Figures
Table 2.1 Quality control steps completed with genotyped variants prior to principal
component analysis.
Filter
Baseline dataset
Remove duplicate variants & indels
Remove variants with >10% missingness
Remove samples >3% missingness
Remove one pair of duplicate samples (the pair with higher
missingness)
Remove variants maf<1%
Remove variants with >5% missingness
Remove samples with >5% missingness
Remove samples outside heterozygosity filter (f coefficient >0.3)
Remove samples with pedigree vs genetic sex mismatch
Remove variants violating hwe (p-value<1e-10)
Remove variants with allele/strand mismatch (vs. 1000 genome panel
variants)
Remove control samples
Pre principal component analysis sample
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Samples Variants
3,739
1,849,381
1,796,564
1,771,718
3,584
3,508
921,083
917,256
3,506
3,505
3,387
914,301
843,850
3,313
3,313

843,850

Table 2.2 The number of variants imputed for each chromosome using TOPMed panel.
The total number of variants were 60,941,072.
Chromosome

Imputed
Variants

Chromosome

Imputed
Variants

1

4,889,931

7

3,575,429

2

5,277,930

8

3,426,745

3

4,370,489

9

2,690,807

4

4,310,328

10

3,008,743

5

3,980,182

11

454,157

6

3,782,515

12

2,931,624

13

2,183,250

19

1,393,198

14

1,948,976

20

1,379,845

15

1,781,331

21

810,711

16

1,984,703

22

865,521

17

1,774,596

X

2,388,886

18

1,731,175

Total

60,941,072

Table 2.3 List of the phenotypes selected for the study.

Selected phenotype
Body Mass index
WAIST Circumference

WAIST to HiP Ratio

C-reactive Protein
Interleukin-6
Interleukin-8

Fibrinogen

Reason for inclusion
Associated genes also linked to inflammation 114
A reliable indicator of visceral adiposity, and
significantly correlated inflammation and
cardiovascular risk factors 213
A reliable indicator of visceral adiposity, and
significantly correlated inflammation and
cardiovascular risk factors 214
Plays a leading role between adiposity-CVD 215,216
Associated genes significantly linked to variation
in adiposity in Europeans 217
Inflammatory marker significantly raised in
hyperlipidemia and cardiovascular diseases
context 218
Significant correlation with adiposity markers 219
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Table 2.4 Descriptive Distribution of anthropometry and inflammatory phenotypes.
Phenotype (unit)

Min.

1st Qu.

Median

Mean

SD

3rd Qu.

Max.

N

13.29

26.31

29.88

30.91

6.96

34.31

70.48

3180

WHR-Female(wc/hip*100)

36.39

86.5

91.3

91.19

7.93

96.03

184.79

2087

WHR-Male(wc/hip*100)

66.31

91.6

95.98

95.93

7.59

100.21

215.79

1093

Waist-female (cm)

37

90

99.5

101.03

16.56

110

186

2088

Waist-male (cm)

68

94

102.5

104.16

15.2

112

168

1096

CRP (mg/L)

0.08

2

3.99

7.97

14.3

8.1

242.5

1937

IL-6 (pg/dl)

0.01

1.4

2.68

5.6

20.97

4.91

521.38

1362

IL-8 (pg/dl)

0.0

3.42

4.69

6.53

7.13

6.81

100.01

1499

Fibrinogen (mg/L)

0.05

0.51

0.8

0.95

0.74

1.18

11.89

2544

AGE(Year)

15.00

33.00

45.00

49.92

17.22

59.00

94.00

3180

2

BMI (kg/m )

Table 2.5 Proposed cut-points for exclusion of phenotypic outliers under hybrid approach.
Populations

Proposed
Cutpoints

2.7 (1.2–6.0)

Hispanics 220

± 2.4 SD

pg/dl

1.6 (0.8–2.8)

Hispanics 220

IL6

pg/dl

0.5(0.5-10)

Hispanics 221

IL6

pg/dl

0.9(0.8)

Hispanics 221

IL8

pg/dl

3.7(2.3)

Hispanics 222

IL8

pg/dl

Marker

Unit

Median(IQR)

CRP

g/dl

IL6

Mean(SD)

Hispanics 223

4.4(3.2–5.9)

Fibrinogen

g/L

2.8(0.75)

Mixed 224

Fibrinogen

g/L

3.6(3.4)

Mixed 225

± 2.8 SD

± 2.6 SD

± 2.8 SD

WHR-F

WC/H

± 3.0 SD

WHR-M

WC/H

± 3.0 SD

WC-M

cm

± 3.0 SD

WC-F

cm

± 3.0 SD
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Table 2.6 Descriptive distributions of study phenotypes after exclusion of outliers under
hybrid method.
Phenotype (unit)

Min.

1st Qu.

Median

Mean

SD

3rd Qu.

Max.

N

16.16

26.30

29.86

30.76

6.53

34.25

57.21

3159

WHR-Female(wc/hip*100)

69.89

86.54

91.30

91.17

7.08

96.00

116.39

2077

WHR-Male(wc/hip*100)

77.87

91.70

96.01

95.94

6.40

100.22

113.58

1084

Waist-female (cm)

62.00

90.00

99.50

100.77

15.52

109.50

158.00

2072

Waist-male (cm)

68.30

94.00

102.50

103.95

14.62

112.00

157.00

1089

CRP (mg/L)

0.35

2.00

3.90

6.23

6.93

7.73

50.03

1880

IL-6 (pg/dl)

0.16

1.44

2.68

4.32

5.74

4.87

47.38

1336

IL-8 (pg/dl)

1.10

3.42

4.67

5.67

3.58

6.65

25.56

1448

Fibrinogen (mg/L)

0.15

0.51

0.80

0.92

0.56

1.17

4.06

2506

AGE(Year)

15.00

33.00

45.00

49.92

17.22

59.00

94.00

3159

2

BMI (kg/m )
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Figure 2.1 Minor Allele Frequency (MAF) distribution of genotyped variants.

Figure 2.2 Proportion of missingness per variant.
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Figure 2.3 Per sample missingness vs autosomal heterozygosity. No sample was observed
outside proposed threshold (median ± 3 × interquartile range for autosomal heterozygosity)
which would have been indicated with black colored data points.

Figure 2.4 Distribution of F ratio coefficient. Each data point is an individual. Green color
represents female pedigree sex, and shape indicates genetic sex where round shape suggests
ambiguous genetic sex, trigon is male and square is genetic female sex. A number of
mismatches between genetic vs pedigree sex observed.
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Figure 2.5 Sex vs autosomal heterozygosity. Each data point is an individual; color
represents genetic sex where blue is pedigree recorde female and red is male. Results are
consistant with F ratio coefficient distribution (Figure 2.4).

53

Figure 2.6 Eigensoft calculated ancestry outliers. Note that the pattern of ancestry outliers
is not consistant when different PCs are compared.
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Figure 2.7 Hardy-Wienberg Equilibrium. A negligible number of variants were found
outside of the significant thresholds for HWE (< 10-6, < 10-20, <10-50).

Figure 2.8 Kinship structure comparing identity by descent (IBD) parameters; IBD1 of 1
or close indicates child-parent kinship because they share 50% of their DNA markers.
IBD0 is defined ~1 for pair of unrelated individuals if no recent shared ancestry. IBD2 of
1 suggest ~100% ancestry genetic concordance which can only be observed in
monozygotic twins or duplicated samples. Approximately 76 pairs had >80% genetic
concordance which suggest either duplicity or monozygotic twins (left down corner).
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Figure 2.9 Projection of the first three PCAir for CCHC over 1000G individuals for
ancestry inference. Nearly all individuals cluster with American ancestry population,
which entail Mexican and Native ancestry groups. (Note: CCHC (study group),American
(AMR), East Asian (EAS), African (AFR), European (EUR), Southeast Asian (SAS)).

Figure 2.10 Parallel plot of the first 10 PCs. Nearly all individuals cluster with American
ancestry population, which entail Mexican and Native ancestry groups. Y-axis values were
scaled with “uniminimax’ method with 0 set for minimum observed measure and 1 for
maximum. Colors represent ancestry.
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Figure 2.11 Screeplot for PCs. Note that PCs beyond the 3rd do not capture significant
variation in the data.

Figure 2.12 Scatter plot of PCAir1 vs PCA1. No practical difference could be observed.
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Figure 2.13 Distribution of phenotypic markers using observations from visit 1 & 2.
Skewed distributions of inflammatory traits suggest presence of some extreme measures.

Figure 2.14 Log-transformed distributions of age, anthropometry and inflammation
phenotypes.
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GWAS AND PLEIOTROPY
A GWAS primary assessment tool used to identify thousands of genetic loci associated
with one or multiple biologic and disease traits. In this chapter, mixed models GWAS were
used to investigate association of SNPs with 9 anthropometric and inflammatory
phenotypes. In the second part, the GWAS summary statistics were utilized to investigate
pleiotropy across anthropometry and inflammatory domains. Cross-trait look-ups
identified SNPs associated with metabolic, inflammatory and brain disease traits within or
in close proximity to 3 genetic regions on chromosome 3, 12 and 18 with suggestions for
pleiotropy.
1. Background

Since the early 2000s, GWAS have been extensively used to locate single-nucleotide
variants associated with complex phenotypes, including body mass index (BMI)226,
measures of central obesity227-229, and inflammation105,230. A portion of genetic variants
that have been primarily identified in association with anthropometric traits and
inflammation have also been noted to display functional relationships with other
domains159,231. For instance, obesity-associated variants in the LEPR, APOC1232, GCKR,
MC4R159, CSN1S117, FDFT1 and PCCB genes107 have also been associated with
inflammation. Conversely, genetic loci associated with inflammatory markers233 also
appear to be associated with variations in body weight and adiposity levels118,119.
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Besides genetics, other clinical234, pharmacological234 and observational235 studies have
also demonstrated synergistic associations between adiposity and inflammation. These
overlaps may indicate that anthropometric traits, which are often used as surrogates for
adiposity, may share certain biological pathways with the inflammatory processes that
underpin cardiovascular diseases. Termed pleiotropic variants127, these multi-effect
variants have been associated with multiple phenotypes107.
Despite strong evidence for pleiotropy, existing studies have limited inferential utility
because the majority of genetic research has been conducted in populations with European
ancestry. This well-attested lack of diversity in genetic studies139 not only hinders the
discovery of more variants associated with underlying functional pathways, a phenomenon
referred to as missing heritability236, but also poses considerable problems for the
functional characterization of known variants due to differences in allelic frequency237,
linkage disequilibrium (LD)238, and genetic architecture among populations with divergent
genetic ancestries from Europeans239,240.
These genetic dissimilarities extend to phenotypic traits including inflammatory markers
and adiposity indices. Significant discrepancies have been identified in the distributions of
inflammatory markers across various ancestry groups, even after adjusting for differences
in adiposity configurations142. Additionally, BMI-adjusted distributions of adipose tissues
suggest distinct ancestry patterns241, as Hispanics, in comparison to European ancestry
populations, tend to exhibit higher levels of visceral fat242. These observations have
suggested that various functional pathways are likely to be affected by ancestry-specific
pleiotropic variants. Thus, a genome-wide, systematic, and comprehensive evaluation of
pleiotropy in the Hispanic/Latino population is needed.
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In this study, using genetic observations obtained from CCHC, GWAS tests were
performed to assess the associations between 3 anthropometric traits including BMI, WHR,
and WC measurements and 4 inflammatory markers including IL-6, IL-8, fibrinogen, and
CRP.
During the second step, using summary statistics from the GWAS analysis, the aSPU
method243 was employed to examine pleiotropy among the phenotypes of interest. Finally,
bioinformatic annotation of top signals was conducted.
2. Methods
2.1.

Study population

CCHC is a cohort of Mexican Americans residents of Cameron county in the state of
Texas. Elevated prevalence of cardiovascular risk factors including type 2 diabetes,
dyslipidemia and overweight in this group indicate a population highly susceptible to
adverse metabolic events 166.

Out of 5,000 individuals recruited for the cohort, a sub sample of 3313 genotyped
individuals are included in this study. Genetic measurements were completed at the
Vanderbilt University Medical Center genotyping core facility, VANTAGE, using MEGAEX Array panel. The median proportion of European ancestry in the cohort is 45.8%,
African 11.0%, and Amerindian 42.9%.

2.2.

Covariate selection

GWAS studies involving WHR, WC244,245, and inflammatory traits246 often incorporate
BMI as a covariate to identify genetic effects that are independent of overall obesity.
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Univariate regression was used to examine the associations between the phenotypes
included in the present study. Significantly associated variables identified by univariate
analysis were incorporated as covariates in the GWAS analysis.
Linear regression models, both with and without adjustments for sex and age, were
employed to determine how many ancestry principal components (PCs) were significantly
associated with variations in phenotypic measurements and should, therefore, be used as
covariates. Age and sex were universally employed as covariates with association tests.
Phenotypes were log-transformed and fit into linear regression models, adjusted for age,
sex, BMI, and the first three PCs; BMI was not used during fibrinogen and IL-8 analyses
because no association was observed between these variables during the univariate
analyses. These residuals were subsequently used as the outcome variables in GWAS tests
(supplementary Figure 3.1).
2.3.

GWAS test

Covariate-adjusted GWAS typically focuses on associations between single-nucleotide
variants and phenotypic measures. In contrast to methods that test a small number of
candidate regions, GWAS studies investigate a larger number of genotyped/imputed
variants that are spread across the entire genome. Therefore, GWAS is principally a
hypothesis free approach247.
Residuals were used to perform GWAS testing (see chapter 2). A score-based, mixed
linear regression model was adopted, and a pairwise kinship coefficient was incorporated
as a random effect parameter. The kinship threshold was set to a third-degree relationship,
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which equates to first-degree cousins. All phenotypes were treated as continuously
measured variables.
The tests assumed additive model of association where the SNP effect is proportional to
the presence of risk allele. For those samples harboring two risk alleles receive higher
scores than those who were heterozygous for the locus, and zero score is assigned if both
non-risk increasing alleles are identified248. Because imputed SNPs constituted the
dominant share of the variants, the two most common methods of assigning SNP score
were the best guess genotype (posteriori) which assigns a discrete count of risk alleles
(0,1,2), and allele dosage which is the estimated (expected) fractional counts of effect allele
at each SNP for each individual, ranging continuously from 0 to 2. The first method is
sensitive to imputation quality while the second approach appears to be effective and
efficient to account for the uncertainty in the imputed genotypes249, particularly when
expected effect sizes are small. Indeed, regression analysis of a sample ~20K SNPs with
BMI phenotype showed a median of 8% [IQR: 3%, 21%] difference in standardized effect
sizes using the best guess vs dosage method. Therefore, SNP dosages were used for GWAS
tests.
For WC and WHR, GWAS were conducted for both sexes, separately, to account for the
inherent sexual dimorphism of these traits181. A total of 9 GWAS were completed including
GWAS for BMI, WHRBMI-adj in females, WHRBMI-adj in males, WCBMI-adj in females,
WCBMI-adj in males, CRPBMI-adj, IL-6BMI-adj, IL-8 and fibrinogen. Additionally, sex-specific
GWAS for WHR and WC were meta-analyzed, using the inverse-variance weighted
method, to create sets of sex-combined GWAS results for both traits.
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Statistical significance was set at a Bonferroni-corrected level [5 × 10−8] to adjust for
multiple testing. Manhattan plots were used to visualize the GWAS results, in which the
negative log of the p-value for each variant-phenotype association test was plotted against
each genomic region. Established genetic loci for traits of interest were marked in the
Manhattan plots. This step also served as a quality control step to determine whether the
GWAS tests successfully replicated known SNPs and could, therefore, be
methodologically validated.
GWAS tests were performed using R package GENESIS174, while visualizations were
completed with R package EasyStrata250. WHR and WC GWAS meta-analyses were
performed with the METAL package251. Computations were completed on the Longleaf
server for the University of North Carolina, Chapel Hill.
2.4.

Post-GWAS sensitivity analysis

To assess whether the observed signals were driven by less frequent or poorly imputed
variants, which can pose a challenge for the replicability of results, a series of filtration
criteria were utilized including:
•

MAF<5%

•

Minor allele count <30 (MAF × N (sample size))

•

Imputation quality <80%

•

Effective sample size (EffN) (2×MAF× (1-MAF) ×Imputation quality
(%)×N) <30

64

The threshold for each quality control (QC) criterion was inferenced from empirical
distributions, as well as a review of the literature252,253. After obtaining different subsets of
GWAS results with each filter (or combination of filters) for each trait, QQ-plots and
genomic inflation factors (λ)250 were used to assess the type 1 (false-positive) error. An
inflation factor (λ) value of >1.05 would be indicative of mild inflation, whereas a value
>1.1 would indicate serious inflation based on the observed p-values, which would
necessitate the adoption of stricter genomic-control measures.
2.5.

Pleiotropy test

To perform an exploratory analysis of genetic correlations between phenotypes, a
pairwise genetic distance matrix was constructed based on genetic similarities. The aSPU
199

test was utilized to perform the multivariate assessment of genetic pleiotropy. A major

strength of the aSPU test over other methods is that the loss in power is negligible when
the number or portion of non-associated variants increases203, which is a distinguishing
feature in the context of this study, in which univariate GWAS results were inferred from
smaller sample sizes.
Briefly, the method aggregates information across n phenotypes for a given SNP by
taking the sum of its univariate GWAS Z-scores each raised to some power γ, so that a
higher γ increases the influence of strongly associated phenotypes on the score. By
allowing γ to take one of many competing values (1,2,…,∞), aSPU selects a maximally
efficient scheme to detect combined phenotype effects on the entire group of phenotypes.
A set containing trait-specific GWAS-inferred Z-scores (from all contributing
phenotypes) was constructed. Pleiotropy analysis was performed using the JaSPU

65

(github.com/kaskarn/JaSPU) package, with the number of iterations set to 1011. This
program relies on a Markov Chain Monte-Carlo (MCMC)

254

iterative process, which is

applied to univariate Z-scores, estimated by inverse-variance-weighted meta-analysis to
generate pleiotropic p-values.
Finally, the covariance matrices for pleiotropy results were examined to ensure that no
dimension (i.e., phenotype) exhibited considerably small or large eigenvalues; excessivelylarge eigenvalues are indicative of the disproportionate contribution of a phenotype to a
pleiotropic signal, whereas very small values indicate the opposite, and either result would
suggest that the underlying hypothesis for pleiotropy would not hold, at least for some
phenotypes.
Exploratory genetic correlation analyses [prior to pleiotropy] were completed using
GCTA package 255.
2.6.

In-depth probe of suggestive pleiotropic signals

All variants with a pleiotropic p-value of paspu< 5 × 10−5 were extracted from the output.
From this output, a subset of variants with a more stringent significance level (paspu < 5 ×
10−6), which were robust to post-GWAS quality assessments and harbored clusters of
variants with low SNP-specific (γ < 4) scores were selected. The final criterion provides a
mechanism for grouping loci from the most to least likely to be pleiotropic.
Among these select variants, the univariate negative log p-values from the GWAS results
were extracted and incorporated into heatmap plots to elucidate which phenotype(s) were
the likely drivers or contributors to the pleiotropic signals. Heatmap plots were constructed
using gplots R package 256.
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2.7.

Functional evaluation of pleiotropic signals

For selected loci with evidence of pleiotropy, the GWAS catalog was probed to identify
whether any variant within the selected 1 Mbp distance on both sides of each genomic
region and in LD with variants within the region (D`>0.5) had previously been reported in
association with the phenotypes under study or with any other traits/diseases and how
commonly theses variants were identified. The findings were tallied by phenotypic
domains from all suggestive loci. GWAS catalogue (ebi.ac.uk) and NCBI
(ldlink.nci.nih.gov/?tab=ldtrait) were used for this assessment.
3. Results
3.1.

Descriptive statistics

Descriptive distributions of the study population are shown in Table 3.1. The ages of the
participants ranged from 15–94 years, with a median of 45 years. The BMI (weight (kg)/
height (m2)) distribution indicates that this cohort is three-quarters overweight (BMI ≥ 25),
one-half obese (BMI ≥ 30), and at least one-quarter moderately-to-severely obese (BMI ≥
35).
The median values for WHR (WC/hip (cm) × 100) and WC (cm) in women were 91.3
and 99.5, respectively, whereas, in men, these values were 96.0 and 102.5. The difference
between the mean and median values of inflammatory markers indicated skewed
distributions, with the exception of fibrinogen, with a mean value of 0.92 g/L, which is
lower than the average ranges (1.5-4.5) reported in other studies for mixed populations
224,225

.
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3.2.

GWAS results

Phenotypic residuals extracted from linear regression analyses were used as dependent
variables in mixed model GWAS tests. A total of 9,262,347 variants, covering
chromosomes 1-22, passed imputation quality control and were, therefore, included in the
GWAS tests. Manhattan plots of the GWAS results for BMI, WCBMI-adj in women, WCBMIadj

in men, sex combined WCBMI-adj, WHRBMI-adj in women, WHRBMI-adj in men, CRPBMI-adj,

IL6BMI-adj, IL8, and fibrinogen are shown in supplementary Figures (3.2a–j) respectively,
where dots represent variants, x-axes demonstrate genomic region [by chromosome
number and base pair position] and y-axes demonstrate negative log of GWAS p-value of
each SNP.
In the sex-combined meta-analyses for the WHRBMI-adj GWAS (Figure 3.1), two GWASsignificant signals (P<5.0 x 10-8) were observed for WHRBMI-adj, on chromosomes 6 and 8.
The signal on chromosome 8 corresponds to a locus previously associated with WHR,
whereas the signal on chromosome 6 has not been previously reported in the literature
(Table 3.2, Figure 3.1). No GWAS-significant variants were observed in either known loci
(denoted by the blue color) or other regions for any other trait.
3.3.

Sensitivity analyses

Variants beyond the significance threshold set for the study (i.e., p-value < 5 × 10−6) for
each trait (supplementary Table 3.1) were examined to assess whether the top signals were
driven by less frequent or poorly imputed SNPs, which may affect the replicability (i.e.,
generalizability of observed signals). Supplementary Table 3.1 shows the counts of
significant variants remaining after the application of each (or the combination of) QC
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criteria for MAF, MAC, imputation score, and effective sample size. Few signals were
likely driven by less common variants (i.e., MAF < 5%), no poorly imputed SNPs were
identified in the results. Application of MAC & MAF resulted in near maximal removal of
less common variants compared to baseline GWAS results (i.e., non-filtered GWAS) and
therefore adopted as the post-GWAS filtration criteria.
Comparisons of inflation factors for each subset illustrated that no substantial inflation
affected the association tests, as all λ values ranged from 0.99–1.03, well below the 1.05
threshold level (supplementary Table 3.2). Therefore, no genomic control application was
deemed necessary. However, few Q-Q plots suggested deflation, particularly at the left tail,
where fewer highly significant variants were observed than expected, particularly for those
GWAS subsets that excluded less common variants (i.e., MAC>30 and MAF>%5 filtered
GWAS subsets) (Figure 3.3a–d).
3.4.

Pleiotropy results

The preliminary examination of genetic correlations between phenotypes, inferred from
GWAS summary results, illustrated that both inflammation and anthropometry-associated
variants clustered with their respective phenotypic domains (supplementary Figure 3.4).
However, fibrinogen was a notable exception, which correlated more closely with WCBMIadj

in men than with inflammatory markers.

A Manhattan plot of the pleiotropy results included no significant GWAS variants, either
in regions known for associations with any of the study traits (denoted by a blue color) or
novel loci (Figure 3.2). However, suggestive signals were identified in several
chromosomes, including 1, 3, 12, 18, and 19, which merited further evaluation. The
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absence of very small or large eigenvalues in the covariation matrix made it unlikely that
the observed pleiotropic outcomes were driven by any solitary trait (supplementary Table
3.3).
The in-depth interrogation of the locus on chromosome 3 revealed that IL-6, BMI, and
WC in men were the primary drivers of the pleiotropic signal (Figure 3.3a). For the locus
on chromosome 12, GWAS results from CRP, BMI, fibrinogen, WHR, and WC in women
were contributors to the signal (Figure 3.3b). However, for the locus on chromosome 18,
the pleiotropic association appeared to be disproportionately driven by WHR in women,
with fibrinogen playing a minor part (Figure 3.3c). Of the three loci, the region on
chromosome 12 appeared to be the most promising for pleiotropic potentiality. The signals
on chromosome 1 and 19 only contained solitary variants for each and did not include
clusters of associated SNPs.
Finally, the online library of GWAS catalog was probed to explore whether any of the
variants in the selected regions had previously been reported for any phenotype or are in
LD (D`>0.5) with variants identified for those phenotypes. In two of three regions, on
chromosomes 12 and 18, several variants were reported in association with energy intake
or WHR, although they were not identified often (Table 3.3).
In the target region on chromosome 3 (bp chr3:4120729-4262732, ±1Mbp on either
directions), a significant number of variants were observed in association with brain
function and diseases, lipid levels, inflammation, and metabolite levels; few were identified
for body weight and type 2 diabetes. For the locus on chromosome 12 (bp chr12:4447633244621041, ±1Mbp on either directions), SNPs linked to variations in anthropometric traits
(WHR), inflammatory diseases, and gut microbiome were more frequently reported. For
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the locus on chromosome 18 (bp chr18:61577041-61588083, ±1Mbp on either directions),
variants associated with blood pressure, energy intake, allergies, autoimmune conditions,
and cancer were identified (Table 3.3).
4. Discussion
The study results provided suggestive evidence for at least 3 pleiotropic signals
associated with both adiposity and inflammation which indicated a considerable degree of
genetic overlap.
Two regions on chromosomes 6 and 8 exceeded the GWAS significance level for sexcombined meta-analyzed WHR results (Table 3.2, Figure 3.1). Although the signal on
chromosome 8 has previously been reported, the signal on chromosome 6 has not been
previously recorded in the GWAS libraries. GWAS-significant SNPs in the novel locus
occur in the region between LRFN2 and LOC101929555. Variants in LRFN2 have been
reported in association with BMI

257,258

, type 2 diabetes

259

, lipid profiles

260

, cognitive

abilities 261, and WHR 262. LOC101929555 has not yet been functionally characterized.
A number of loci that have been widely reported and mapped for associations with
anthropometric and inflammatory traits, including the SNPs in IL6 on chromosome 7 (for
IL-6)

263

or FTO on chromosome 16 (for BMI)

264

, did not exceed the GWAS threshold

level. Although larger studies have ascertained the transferability of a sizeable proportion
of phenotype-associated common variants across various ancestries
anthropometric

266,267

and inflammation-associated variants

267

, including

, important ethnic

differences were also noted 268-270, even in known genomic regions 271.
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265

Although these observed patterns could suggest an ancestry-specific association pattern,
caution must be exercised because differences in the LD structure 239, study sample sizes
238

, and dissimilarities in variant coverage (SNP tagging

272

) can all induce differences in

the GWAS signals across various study settings or ethnicities 271.
Although no variants exceeded the GWAS significance level in the pleiotropy analysis,
suggestive signals were identified on chromosomes 3, 12, and 18 (Figure 3.2 & Figure
3.3a-c). Multiple phenotypes appeared to contribute to the loci on chromosomes 3 and 12,
whereas the signal on chromosome 18 was primarily driven by WHR in women.
Additional variants were also identified: one on chromosome 1 (rs952499) overlapping
gene ABCA4, and another on chromosome 19 (rs669560) overlapping ZNF708, with strong
pleiotropy p-values (< 5 × 10−7). However, in both instances, the signals were driven by
solitary SNPs that were not in tight [or loose] LD with any other variants that exhibited
significant pleiotropy p-values.
A review of the GWAS library to identify suggestive pleiotropic loci showed that an
extensive number of variants were already reported for associations with a range of
metabolic and inflammatory functions. For the probed region on chromosome 3, a sizeable
number of SNPs were shown to be associated with brain function and diseases, liver
function, triglyceride, inflammation, type 2 diabetes and body weight(Table 3.3).
Similarly, for the suggestive region on chromosome 12, many variants were associated
with anthropometric indices, and inflammatory diseases. The third probed locus on
chromosome 18 also contained variants associated with inflammation, WHR and blood
pressure indices.
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There few methodological considerations. The Q-Q plots for the IL-6 and IL-8 GWAS
results suggested deflation at the left tails (supplementary Figure 3.3a-d). Factors including
the overcorrection of GWAS test statistics in polygenic phenotypes (such as cytokines) 273
and adjustments for pairwise kinship in mixed-model GWAS tests
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could potentially

induce deflation. However, the severity of deflation increased when less common variants
(MAF < 5% and MAC < 30) were excluded, which indicated that deflations were likely
induced by reduced power (supplementary Figure 3.3c and 3.3d).
The age distribution of the participants suggested a middle-aged cohort that was slightly
older than the general Hispanic population (Table 3.1). The prevalence of obesity was
higher than the national average level for the Hispanic population, as reported by the
Centers for Disease Control and Prevention (CDC) for the 2017–2018 period 275 (45% vs.
>75% in this study). However, the distributions of WHR and WC suggested that central
obesity, likely caused by an accumulation of visceral fat, represents the prevailing form of
adiposity, as over three-quarters of both men and women had measures above their
respective threshold levels [WHR > 85 in women and WHR > 90 in men 276] for obesity.
These results, together with the presence of higher levels of inflammatory markers,
presented an opportunity for pleiotropy assessment due to the increased statistical power
despite a modest study sample size.
Fibrinogen was the only inflammation marker with lower distribution (mean = 0.92 g/L)
compared with the average range reported by other studies (1.5–2.5 g/L) 277,278. However,
this marker is known to exhibit considerable within-sample variability, even in healthy
individuals 279. Additionally, fibrinogen measures were significantly correlated with WHR,
WC, and interleukin levels, which suggested that the observed values may be a function of
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the caliber of the assay rather than the reduced distribution of this marker in this study
group.
In conclusion, the overlap in SNP associations with similar phenotypic domains for all
three regions underscores the complexity and interrelatedness of traits that are otherwise
viewed as independent and highlights the need for a greater focus on pleiotropic SNPs that
can provide novel insights into the underlying mechanisms that drive these traits. The high
prevalence of adiposity and inflammation in this cohort highlithed the need for pleiotropy
study in this cohort with high susceptibility to adverse cardiovascular events
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5. Tables and Figures
Table 3.1. Distributions of inflammatory and anthropometric phenotypes and age among
Cameron County Hispanic Cohort (CCHC) subjects.
Phenotype (Unit)

Min.

2

1st Qu. Median

Mean

SD

3rd Qu.

Max.

N
3159

16.16
BMI (kg/m )
Waist-female (cm) 62.00

26.30

29.86

30.76

6.53

34.25

57.21

90.00

99.50

100.77 15.52

109.50

158.00 2072

Waist-male (cm)
WHR-Female*

68.30
69.89

94.00
86.54

102.50
91.30

103.95 14.62
91.17 7.08

112.00
96.00

157.00 1089
116.39 2077

WHR-Male*
CRP (mg/L)
IL-6 (pg/dL)

77.87
0.35
0.16

91.70
2.00
1.44

96.01
3.90
2.68

95.94
6.23
4.32

6.40
6.93
5.74

100.22
7.73
4.87

113.58 1084
50.03 1880
47.38 1336

IL-8 (pg/dL)

1.10

3.42

4.67

5.67

3.58

6.65

25.56

1448

Fibrinogen (g/L)

0.15

0.51

0.80

0.92

0.56

1.17

4.06

2506

Age(year)

15.00

33.00

45.00

49.92

17.22

59.00

94.00

3161

*reporting unit: Waist/Hip(cm)×100

Table 3.2. GWAS significant variants in sex-combined meta-analyzed WHRBMI-adj
GWAS analysis.
Chr.*
6
6
8
8
8
8
8
8

Bp
Rsid
Nearest Genes
Position**
40810472 rs12524956 LRFN2,LOC101929555
40810278 rs12524922 LRFN2,LOC101929555
72499840 rs202053146
EYA1, MSC
72524159
rs1424869
EYA1, MSC
72488774
rs972738
EYA1, MSC
72484519 rs59354633
EYA1, MSC
72492249 rs35727416
EYA1, MSC
72473729 rs10504510
EYA1, MSC

*Chr=Chromosome, **Bp= base pair
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Z-score

P-value

-5.61543
-5.49004
5.54286
5.52103
5.53007
5.52962
5.46058
5.4889

1.96E-08
4.02E-08
2.98E-08
3.37E-08
3.20E-08
3.21E-08
4.75E-08
4.04E-08

Table 3.3. Functional probe of three loci on chromosome 3, 12 and 18 with suggestion
for adiposity-inflammation pleiotropy.
chr3:4120729-4262732

chr12:44476332-44621041

Brain function or diseases

Within ± 1 Mbp of the
region and in LD (D`>0.5)
with variants
WHR

Blood proteins/metabolites

Height

Inflammatory diseases/markers
Weight
Type 2 diabetes
Metabolite levels
Lipid levels (triglyceride)
Liver function (AST)
Eye function/diseases

Idiopathic scoliosis
Immune response
Gut microbiome

Within ± 1 Mbp of the region and
in LD (D`>0.5) with variants
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chr18:6157704161588083
Within ± 1 Mbp of the
region and in LD (D`>0.5)
with variants
Allergy, inflammatory,
autoimmune diseases
Anthropometric traits
(WHR)
Energy intake
cancer
Blood pressure

Figure 3.1. Sex-combined meta-analyzed GWAS for WHRBMI-adj. Blue color denotes
known loci.

Figure 3.2. Pleiotropy Manhattan plot. Dots represent genomic variants; x-axis indicates
chromosome number and base pair position for single nucleotide polymorphisms (SNPs)
and y-axis demonstrate pleiotropy p-value for each variant. Blue color denotes known loci
associated with phenotypes contributing to pleiotropy.
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Figure 3.3a-c Heatplots of variants with trait-specific GWAS pvalues of <5 × 10−5
located within the three loci with suggestive evidence for pleiotropy; rows show variants
and columns display traits. Row clusters represent euclidean distances between variants,
and column clusters are based on similarity of trait-specific pvalues. Color transition (red
to yellow) demonstrates change in trait-specific negative log GWAS pvalue for each
variant where brighter colors indicate higher significance level.
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6. Appendices

Supplementary Figure 3.1. Distributions of phenotypic residuals used as depedent
variables for GWAS tests; residuals were extracted from linear regression of logtransformed phenotypes, regressed over age, sex, first 3 PCs and BMI (except for IL8 and
fibrinogen).
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Supplementary Figures 3.2a-i:
a) BMI Manhattan plot

b) WC-Female Manhattan plot (Adjusted for BMI)

c) WC-Male Manhattan plot (Adjusted for BMI)
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d) WHR-Female Manhattan plot (Adjusted for BMI)

e) WHR-Male Manhattan plot (Adjusted for BMI)

f) C-Reactive Protein Manhattan plot (Adjusted for BMI)
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g) Interleukin 6 Manhattan plot (Adjusted for BMI)

h) Interleukin 8 Manhattan plot

i) Fibrinogen Manhattan plot
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Supplementary Figures 3.3a-d. Q-Q plots for IL6 and IL8 GWAS. Note the deflation
with the left tails which suggest fewer highly significant variants were observed than
expected, particularly for GWAS sets with reduced number of variants after exclusion
of less common variants (i.e., minor allele frequency (MAF<%5) & minor allele count
(MAC<30)). (Figures b & d for IL6 and IL8 respectively).
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Supplementary Figures 3.4. Genetic correlation between anthropometry and
inflammatory phenotypes. All phenotypes except IL8, fibrinogen (FIB) and BMI were
adjusted for BMI, age and sex. Blue color in the heatplot represents negative and red a
positive pairwise correlation, while color intensity demonstrates degree of pairwise
correlation. Clusters are based on genetic distance (i.e., overlap of associated genetic
markers).
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FINE-MAPPING PLEIOTROPIC SIGNALS
In this chapter, the results of fine-mapping analysis to distinguish the set of variants with
high posterior causal probability is presented. Three genomic loci on chromosome 3, 12
and 18 with suggestion for genetic pleiotropy between adiposity and inflammation traits
were probed. The locus on chromosome 12 likely harbors two independent signals. The
functional evaluation showed the majority of fine-mapped variants were SNPs with
regulatory features associated with several tissues including inflammation-related cells;
several variants also exhibited regulatory features associated with dipocytes. Results
underscored potential contribution of regulatory variants in pleiotropy.
1. Background
Both GWAS and pleiotropy studies have provided essential, initial evidence linking
genetic variants with biologic traits or diseases. However, GWAS and, by extension,
pleiotropy assessments, which primarily rely on summary statistics obtained from GWAS
studies, cannot reveal the functional consequence of significant variations.
GWAS-identified signals are typically represented by a ‘lead’ SNP, which has the
strongest (i.e., lowest) p-value in the suspected region. This lead variant may not directly
affect phenotypic expression but, rather, may be a proxy for a ‘true’ causal variant due to
LD, which induces strong correlations between SNPs. Overlap or proximity with a coding
region does not necessarily imply causality280. Further complicating the picture, multiple
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causal and apparently independent variants within a single region can act through joint
allelic effects on the same haplotype125.
The biological interpretations of associations between likely causal variants are highly
dependent on the genomic region in which the variants are located. Over 90% of the GWAS
variants are in non-coding locus and do not directly affect messenger RNAs (mRNA)281
transcription. The functional characteristics of these variants can vary greatly when
operating under different cell-tissue environments282.
Such genetic architecture complexities create challenges when attempting to functionally
interpret GWAS and pleiotropy results. Localized analyses of risk-inducing loci must be
performed with considerations for both allelic structures and functional annotations.
The fine-mapping approach assigns a statistical causality probability to candidate
variants located within the GWAS-identified regions283. In other words, this technique is
used to filter GWAS-identified variants and distinguish SNPs that are most likely to be
causal in each genomic region.
Recently, a number of fine-mapping tools have been developed that utilize iterative
algorithms to perform causal variation identification, including Markov Chain Monte Carlo
(MCMC)284, exhaustive125 and stochastic searches285. Most of these tools assume the
presence of a single causal variant for a given region286. However, this assumption may not
reflect true biological reality, particularly when examining complex traits, such as adiposity
and inflammation. Additionally, many fine-mapping packages lack rigorous statistical
framework to incorporate tissue or cell-specific functionality286,287, which could impact
predictive accuracy.
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Thus, two complementary methods, PAINTOR206 and FINEMAP162, were used to
perform the fine-mapping of adiposity–inflammation pleiotropy-identified regions from
CCHC. Although FINEMAP is unable to account for functionality, this program uses an
efficient algorithm that accommodates the identification of multiple causal variants, with
no substantial computational cost162. After they were identified, the fine-mapped
prioritized variants were subjected to functional assessments to determine biologic effect
potentials.
2. Methods
2.1. Genome-wide pleiotropy summary statistics
The dataset consisted of pleiotropy summary statistics for approximately 6 million SNPs.
Pleiotropy statistics reflect the outcomes of univariate GWAS and pleiotropy assessments
performed during a prior round.
In brief, using genomic measurements from N = 3,313 participants from the CCHC study,
a mixed-model, univariate GWAS were conducted, including anthropometric traits (BMI,
WHRBMI-adj, and WCBMI-adj) and inflammation markers (CRPBMI-adj, fibrinogen, IL-6BMI-adj
and IL8; WHRBMI-adj and WCBMI-adj-GWAS were completed in males and females
separately.
Pleiotropy test was subsequently performed using the trait-specific GWAS summary
statistics. Pleitropy results were converted from newer genome build GRCh38 to older
GRCh37 for compatibility with fine-mapping packages.
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2.2. Statistical framework
A traditional approach used to refine association signals is conditional analysis, a
stepwise process that conditions on the variants with the lowest p-values in association
tests until no additional SNPs are identified that achieve the pre-determined p-value
threshold. Although this approach can be informative regarding the potential number of
signal sources for a specific locus, it does not deliver probabilistic measures of causality
for variants.
Bayesian framework has been increasing being adopted as a way to overcome this
problem288. However, a Bayesian approach requires both genotypic and phenotypic inputs,
which become impractical when the sample size or number of variants increases.
Therefore, fine-mapping methods have been extended to use only the summary statistics
from genetic tests, together with SNP correlations obtained from reference panels125.
PAINTOR represents a fine-mapping method that uses the LD structure and Z-scores
from either univariate GWAS or pleiotropy results289. A distinguishing feature of this
approach is that it leverages functional annotations of individual variants to estimate causal
posterior probabilities. This approach is also robust when multiple, distinct causal variants
appear to underlie functionality and in the context of heterogeneous effect sizes.
In addition to PAINTOR, the FINEMAP package162 was utilized. Pleiotropy suggests
functional overlap, interrelatedness, and complexity in the underlying mechanisms, which
can all increase the possibility that multiple causal variants can be found in a given region.
Given the high density of tested variants, the incorporation of functional annotations with
a fine-mapping probe will exponentially increase the computational costs.
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PAINTOR is only efficient for the probing of a maximum of 3 causal variants for variantdense regions. In contrast, FINEMAP package uses a Shotgun Stochastic Search (SSS)
algorithm207 to explore various causal configurations by concentrating its efforts on
configurations with non-negligible probabilities162. FINEMAP computes probabilities
using summary statistics obtained from GWAS (or pleiotropy Z-scores) and pairwise LD
estimates to facilitate the probing of an increased number of causal variants without
computational penalty. Both packages were used complementarily to maximize the set of
variants identified with high posterior causality probabilities.
2.3. Defining fine-mapping loci
From the pleiotropy summary statistics, a subset of variants with a pleiotropic
significance level of Paspu< 5  10−6 was subtracted. Next, the variants were further
subdivided into independent groups based on their chromosome and base pair numbers. In
each locus, variants were ranked by significance level, and the top SNP with the lowest
Paspu value was selected to serve as the index for the region.
All variants within 500 Kbps in both directions of the index were extracted from the
pleiotropy summary statistics. For each SNP, the reference SNP cluster ID (rsid) number,
chromosome, base pair (bp) number, pleiotropy Z-score, Paspu-value, and effective and
alternative alleles were extracted. For the estimation of SNP pleiotropic effect sizes and
standard errors, the following formulas were utilized:
𝛽=

𝑆𝑒 =

𝑧
√2𝑝(1 − 𝑝)(𝑛 + 𝑧 2 )

… (1)

1
√2𝑝(1 − 𝑝)(𝑛 + 𝑧 2 )
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… (2)

where 𝛽 is the effect size, 𝑧 is the Z-score, 𝑝 is the allele frequency, and 𝑛 is the sample
size for the variants.
2.4. Linkage disequilibrium estimation
Pairwise Spearman’s rank correlation coefficients were estimated using the subset of
unrelated individuals in the CCHC, in which each calculated value could vary between
[1,−1] for any given pair. For LD calculations, LDStore2 package290 was utilized, which
uses the binary BGEN file format291, rather than the variant call format (VCF)292, and is
computationally more efficient than similar platforms.
2.5. Functional annotation
Annotation libraries included:
a) enhancer elements from Functional Annotation of the Mammalian Genome project
(FANTOM5)293,
b) various functional annotations from ENCylopedia of Dna Elements (ENCODE)
project294 including transcription factors295, enhancers296 and promoters297,
c) protein coding elements from gene-ENCODE (GENCODE)298,
d) super enhancers299,
e) DNase I hypersensitive sites (DHSs)281 regulatory elements.
The functional annotation of selected regions was performed with the PAINTOR package
in two steps.
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During the first step, all annotations associated with the functionality of the liver, brain,
blood, muscle, adipose tissues, and exon variants were used to annotate variants in the
target loci.
Because a proportion of annotations could overlap and induce multicollinearity,
correlation matrices were created using annotation scores from the annotated loci, such that
each value in the matrices represented a pairwise correlation between a pair of annotations.
One pair of annotations, with correlation values > 0.2, was set to missing.
The removal process was repeated several times until the remaining set of annotations
was roughly uncorrelated (i.e., all pairwise correlations were below the established
threshold). The remaining annotation set was then utilized for the target regions annotation.
2.6. Fine-mapping process
Fine-mapping analysis was completed using PAINTOR at each locus, separately,
incorporating LD scores and annotations files and assuming up to 3 causal variants per
locus. With FINEMAP, analyses were performed by assuming up to 10 causal variants per
region. All variants with posterior causality probabilities > 0.5 were extracted from the
outcomes of both packages to maximize the number of likely causal variants identified at
each locus. These subsets were used for the downstream functional assessments.
2.7. Functional evaluation
Several bioinformatic platforms were utilized
i) Ensemble Variant Effect Predictor (VEP), from Ensemble300 (grch37.ensembl.org/),
was used to determine the effect of each likely causal variant on genes, transcripts, protein
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sequences, and regulatory regions. VEP was also used to perform the Combined
Annotation-Dependent Depletion (CADD) coding score estimation301; this score is widely
used to measure variant deleteriousness. A negative log-transformed CADD score > 10
suggests a high probability of an effect on protein coding.
ii) Enhanced Accuracy in Predicting the Functional Consequences of Non-coding and
Coding SNV (FATHMM-XF)302 is a method for predicting point mutations within the
human genome the probable effect of the predicted point mutation on protein coding: a
score > 0.5 (of a maximum of 1) indicates a likely coding effect, whereas a score > 0.9
indicates a highly pathogenic or protein-altering mutation.
iii) Haploreg is a tool for evaluating the annotation of a noncoding genome at variants on
haplotype blocks, such as candidate regulatory SNPs at disease-associated loci303. This
annotation tools is use to assess the effects of SNPs on regulatory motifs and expression
Quantitative Trait Loci (eQTL), which are genomic regions associated with expression
levels of messenger RNA (mRNA).
iv) ClinVar is a PubMed-supported and publicly available tool for assessing links
between variants and human phenotypes.
2.8. Independence of signals
Lastly, pairwise Spearman’s rank correlation coefficients were calculated between likely
causal variants in each region. A cut-off value of R2 < 0.1 was used to determine
independence, as correlation values below this threshold suggest that the pair of variants
likely represent different functional signals.
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2.9. Visualization of pleiotropic signals.

To perform a more localized visualization of those loci with evidence for pleiotropy,
locuszoom plots304 were employed. For each locus, the variant with the lowest paspu was
selected as the index, and all variants within a distance of 1 megabase pairs (Mbp) were
plotted on either side of the index SNP.

LD between the index SNP and all other variants within the probed region were
calculated using the set of unrelated individuals from the CCHC (i.e., individuals with a
third-degree kinship relationship or more distantly related). The populations used for the
genotyping reference were Hispanics from the Population Architecture using Genomics
and Epidemiology (PAGE II) cohort (pagestudy.org). The fine-mapped variants with high
causal posterior probabilities were marked with distinguishing shape.

3. Results
The analysis of pleiotropy results indicated three regions on chromosomes 3, 12, and 18
with potential for pleiotropic associations. Out of 7,236 variants assessed, a total of 22
variants showed a posterior probability of > 0.5 for all three regions combined. In addition
to 9 variants suggest by PAINTOR, 13 SNPs were distinguished by FINEMAP. The results
in Tables 4.1a–c show the variants with the highest posterior probability of causality in
each locus.
For the locus on chromosome 3 (bp range: 3,653,147–4,650,039), a total of 9 SNPs were
identified with posterior probability values > 0.5 (out of 3,234 SNPs assessed, Figure 4.1).
As noted, all variants are intronic, nonsense-mediated mRNA decay (NMD) SNPs. Both
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the FATHMM-FX and negative-log CADD scores were considerably below their
respective threshold values of 0.5 and 10, which suggested low probabilities that these
SNPs were protein-altering variants.
However, several variants showed either extensive regulatory annotations with
immunity, skin, pancreas, spleen, gastrointestinal, and lung tissues or were in tight LD (i.e.,
R2 > 0.8) with SNPs featuring regulatory annotations associated with those tissues (Table
4.1a). One SNP, rs60505812, featured a regulatory annotation associated with adiposity
tissue, although it was not in high LD with any other regulatory variant.
All variants overlapped with the gene encoding sulfatase-modifying factor 1 (SUMF1)NMD transcript on the reserve strand (Ensemble ID: ENSG00000144455). Estimates from
pairwise LD analysis (Supplementary Table 4.1, Figure 4.1) indicated that likely one causal
SNP exists in this region because the pairwise correlation estimates were generally above
the threshold level of R2 > 0.1.
For the locus on chromosome 12 (bp range: 43,981,459–44,980,751), 8 variants had
posterior probabilities > 0.5 (out of 1,501 SNPs examined, Table 4.1b, Figure 4.2). Similar
to results for chromosome 3, most SNPs featured low coding scores and were intronic and
NMD, except rs440389 and rs277221, which are intergenic with no significant regulatory
features associated with any tissue. The remaining 6 SNPs have variable regulatory
annotations associated with immunity, skeletal muscle, adipose, blood, vessels, lung, and
pancreas tissues.
The most notable variant from this list is rs73093474, which features multiple regulatory
annotations with adipose, immunity, brain, and pancreas tissues, and is also located in a
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region replete with regulatory SNPs. The two variants at the top of the list overlapped with
the

gene

encoding

interleukin

1

receptor-associated

kinase

4

(IRAK4)

(ENSG00000198001); these two variants may represent a second, independent signal
within the region given their negligible pairwise LD with the other likely causal variants
in the region (Supplementary Table 4.2, Figure 4.2). The remaining fine-mapped SNPs
overlapped

with

the

gene

encoding

transmembrane

117

(TMEM117)

(ENSG00000139173).
Finally, for the locus on chromosome 18 (bp range: 61,079,369–62,075,853), 5 variants
exhibited posterior probability values > 0.5 (out of 1,301 SNPs evaluated). The second and
third variants on this list are intergenic, whereas the remaining variants are intronic and
downstream/upstream to regulatory SNPs. The last two variants (rs28483202 and
rs631815) did not exhibit any regulatory annotations with the bioinformatic tools that were
used.
The first and fourth variants overlapped with the genes encoding serpin family B
members 10 (SERPINB10) and 2 (SERPINB2). The last variant on the list, rs631815,
overlapped with both the genes encoding histocompatibility minor serpin domaincontaining (HMSD) and the AC009802.1 region, which has not yet been functionally
characterized.
All variants appeared to point to the same signal, as the pairwise LDs were above the
threshold levels (Supplementary Table 4.3, Figure 4.3).
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4. Discussion
In this study, summary statistics from pleiotropy analysis, information on pairwise
correlations between SNPs inferenced from a set of unrelated individuals in the study, and
functional annotations for regulatory and coding variants from highly referenced libraries,
including ENCODE294 and FANTOM5293, were incorporated to determine the genomic
loci with the highest probability of exerting a causal role on genetic pleiotropy between
adiposity and inflammation.
Functional assessments were intended to expand upon the statistical findings to narrow
the results to those SNPs that may have the most biological relevance. Because adiposity
and inflammation are complex traits305,306 that are highly polygenic307-310, a higher
probability exists for the identification of multiple, independent causal signals, even within
relatively small regions311. Therefore, the fine-mapping analysis using PAINTOR, which
allows the incorporation of functionality, was complemented with FINEMAP outcomes,
both to expand on the credible set of causal variants for each signal and to increase the
probability of identifying additional signals in each fine-mapped region, assuming that
such signals exist.
Based on summary statistics from the pleiotropy analysis, three loci on chromosomes 3,
12, and 18 were identified based on suggestive evidence for contributions to pleiotropy
between adiposity and inflammatory traits in a Hispanic population. After the application
of the statistical approach, 22 variants showed posterior causality probabilities greater than
50% from the 7,236 variants assessed across all 3 regions.
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The index SNPs identified in each region were associated with the most significant pvalues for pleiotropy, including rs200671707 on chromosome 3, rs60939199 on
chromosome 12, and rs4609952 on chromosome 18; however, these three SNPs did not
have high posterior causality probability values. The fine-mapping algorithm may not have
been able to differentiate causal variants when the underlying structure is correlated, and
several significant variants exist.
Highly significant variants from the pleiotropy analysis results may also represent
proxies of ‘true’ causal SNPs that are not presented in the dataset and, therefore, the
observed associations are biased toward the tagged (observed) SNPs312. Evidence exists to
support a role played by topologically associated domains (TADS), which refer to distant
loci that interact with each other313 and are believed to have significant impacts on the
functional genome314. Therefore the GWAS and pleiotropy signals used for this analysis
may have resided in different genomic regions that interacted with the observed locus.
Finally, this lack of causality associated with highly significant SNPs may indicate the
presence of multiple, independent signals; however, the pairwise LD estimates
(Supplementary Table 4.1-3) suggest that only the fine-mapped region on chromosome 12
may harbor an additional independent signal if any such signal exists.
In the fine-mapped region on chromosome 3, a total of 9 variants had high causal
probability values. Two SNPs, including rs60505812 and rs10514654, are notable. The
first variant has regulatory features associated with adipose tissue, whereas the second
variant exhibited regulatory annotations associated with immunity, skin, and intestinal
tissues. A relatively elevated coding score (CADD = 6.8) suggested that the mutation in
rs60505812 may potentially affect mRNA transcription, although the score remains below
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the cut-off value of 10 that denotes mutational significance315. Therefore, in the context of
the protein-coding process, it is less likely to be a high-impact SNP.
All suggestive causal variants in this region overlapped with SUMF1, which encodes
sulfatase-modifying factor 1 enzyme, a protein that catalyzes glycosaminoglycans,
sulfolipids, and steroid sulfates316. Defects in this gene are known to cause multiple
sulfatase deficiency316, a lysosomal storage disease that contributes to the deterioration of
tissues in the nervous system, resulting in motor dysfunction, seizures, and developmental
delays317. However, variants in this gene have also been linked to inflammation in chronic
obstructive pulmonary disease (COPD)318. Furthermore, steroid sulfates play functional
roles in energy homeostasis and inflammation319.
The analysis of the target region on chromosome 12 showed that 8 variants had high
causality probability values. Pairwise LD estimates (Table 4.2b) indicated two different
signals. The two variants at the top of the list overlapped with IRAK4, whereas the
remaining variants were associated with TMEM117. Although the first variant is intergenic,
its only regulatory feature was associated with trophoblast tissue, whereas the second
variant (rs4251527) was linked with regulatory activities in blood and immune cells.
IRAK4 encodes a protein kinase, which is essential during the innate immune response
to Toll-like receptors (TLRs), and its deficiency increases the susceptibility to infections320.
Studies of obese mice showed that the overexpression of TLRs in enlarged adipose tissue
might play an important role in obesity-induced inflammation321.
Two variants in the same region (on chromosome 12) that overlap with TMEM117,
including rs73093474 and rs10506239, merit further interrogation. The first variant has
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regulatory features associated with an extensive number of tissues, including adipose, lung,
brain, lung, and pancreas. The second variant shows regulatory annotation with brain tissue
(Table 4.1b). TMEM117 encodes transmembrane protein 117 and has been associated with
endoplasmic reticulum-stress (ER-stress) and mitochondria-mediated cell death322.
Lastly, after probing the locus of interest on chromosome 18, a total of 5 variants showed
high causality probability values. The first variant (rs6567401) overlaps with SERPINB10,
which encodes a protein that controls the regulation of protease functions during
hematopoiesis

(blood

production)

and

has

been

associated

with

allergic

inflammation323,324. The second variant (rs28483202) is intronic for SERPINB2, which
encodes plasminogen activator inhibitor 2 (PAI2), a protein known to play a role in the
manipulation of immunity325 and is upregulated during allergic responses326. The third
variant (rs631815) is upstream of HMSD, which is primarily expressed in cells of myeloid
lineage327. The remaining two variants are intergenic, although the closest functional gene
is SERPINB2.
Generally, all but a few of the identified variants with high causality probability values
across all three regions were intronic and NMD SNPs. NMD variants are considered to be
regulatory, quality control variants that reduce gene expression errors by eliminating
mRNA transcripts that contain premature termination codons (PTCs)328.
Growing evidence suggests that variations and tissue-specific differences in NMDs can
alter the underlying pathologies of genetic diseases329-331. Notably, interactions between
NMDs and protein-coding variants have been linked to an increased risk of developing
obesity and type 2 diabetes, as reported in one recent trans-ancestry cohort332. The clinical
study of a patient with the early onset of severe obesity was associated with an NMD
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alteration affecting proopiomelanocortin333, which is involved in a wide range of activities,
including body weight regulation.
Overwhelming (>90%) portion of the GWAS variants were discovered in noncoding
genomic regions281. The results from this study underscore the significance of these
regulatory variants and their effects on pathophysiologic processes upstream of physiologic
phenotypes and clinical traits.
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5. Tables and Figures
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Table 4.1a Characteristics of variants with high posterior causal probability in the target
region on chromosome 3 (base pair range: 3,653,147–4,650,039).
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Table 4.1b Characteristics of variants with high posterior causal probability in the target
region on chromosome 12 (base pair range: 43,981,459–44,980,751).
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Table 4.1c Characteristics of variants with high posterior causal probability in the target
region on chromosome 18 (base pair range: 61,079,369–62,075,853).
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Figure 4.1 Regional zoomplot of the suspect pleiotropic locus on chromosome 3. The blue
colored rotated square in the middle represents index variant while strait squares show finemapped prioritized variant with high posterior causal probabilities (>50%). The Rsid label
shows the variant with regulatory feature associated with adipose tissue. Colors show
degree of linkage diequilibrium (LD) with lead (i.e., index) variant in the region. Blue lines
demonstrate recombination rate inferences from Population Architecture using Genomics
and Epidemiology (PAGE II) Hispanic population. The horizontal bar under x-axis show
genes overlapping or close to target region. The variant highlighted here is Non-sense
mediated decay (NMD) variant for sulfatase modifying factor 1 (SUMF1) gene on the
reverse strand (range of the SUMF1 gene transcript Chromosome 3: 3,742,498-4,508,965).
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Figure 4.2. Regional zoomplot of the suspect pleiotropic locus on chromosome 12. The
blue colored rotated square in the middle represents index variant while strait squares show
fine-mapped prioritized variant with high posterior causal probabilities (>50%). The Rsid
label shows the variant with regulatory feature associated with adipose tissue. The
horizontal bar under x-axis show genes overlapping or close to target region. The variant
highlighted here is Non-sense mediated decay (NMD) variant for transmembrane 117
(TMEM117) gene.
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Figure 4.3. Regional zoomplot of the suspect pleiotropic locus on chromosome 18. The
blue colored rotated square in the middle represents index variant while strait squares show
fine-mapped prioritized variant with high posterior causal probabilities (>50%). The Rsid
label shows the variant with regulatory feature associated with adipose tissue. The
horizontal bar under x-axis show genes overlapping or close to target region. Fine-mapping
prioritized variants mostly overlap with serpin family B members 10 (SERPINB10),
SERPINB7 and SERPINB2 genes.
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6. Appendices
Supplementary Table 4.1. Pairwise linkage disequilbrium (LD) among variants with high
posterior causal probability in the target region on chromosome 3. LD can range from R2≈0
[no LD] to >0.99 [very tight LD]. Values indicate variants belong to the same signal [using
the R2>0.1 cutpoint].
SNP

rs2600116

rs35441937

rs2874822

rs10510288

rs6808934

rs60505812

rs952644

rs10514654

rs6777465

rs2600116

1

0.46

0.34

0.76

0.09

0.34

0.39

0.09

0.69

rs35441937

0.46

1

0.81

0.32

0.20

0.76

0.05

0.21

0.26

rs2874822

0.34

0.81

1

0.45

0.19

0.64

0.02

0.20

0.18

rs10510288

0.76

0.32

0.45

1

0.09

0.26

0.29

0.09

0.56

rs6808934

0.09

0.20

0.19

0.09

1

0.1911

0.20

0.90

0.11

rs60505812

0.34

0.76

0.64

0.26

0.19

1

0.10

0.20

0.38

rs952644

0.39

0.05

0.02

0.29

0.20

0.10

1

0.22

0.56

rs10514654

0.09

0.21

0.20

0.087

0.90

0.20

0.22

1

0.11

rs6777465

0.69

0.26

0.18

0.56

0.11

0.38

0.56

0.11

1
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Supplementary Table 4.2. Pairwise linkage disequilbrium (LD) among variants with high
posterior causal probability in the target region on chromosome 12. This locus may harbor
two independent signals [using the R2>0.1 cutpoint].
rs440389

rs4251527

rs277221

rs60995491

rs11182419

rs73093474

rs10506239

rs73094803

rs440389

1.00

0.20

0.15

0.00

0.01

0.00

0.00

0.00

rs4251527

0.20

1.00

0.08

0.02

0.02

0.02

0.02

0.01

rs277221

0.15

0.08

1.00

0.01

0.01

0.01

0.00

0.01

rs6099549
1

0.00

0.02

0.01

1.00

0.01

1.00

0.93

0.88

rs1118241
9

0.01

0.02

0.01

0.01

1.00

0.01

0.01

0.01

rs7309347
4

0.00

0.02

0.01

1.00

0.01

1.00

0.93

0.88

rs1050623
9

0.00

0.02

0.00

0.93

0.01

0.93

1.00

0.83

rs7309480
3

0.00

0.01

0.01

0.88

0.01

0.88

0.83

1.00

Supplementary Table 4.3. Pairwise linkage disequilbrium (LD) among variants with high
posterior causal probability in the target region on chromosome 18. Values indicate
variants belong to the same signal [using the R2>0.1 cutpoint].
rs6567401 rs1243064 rs2689416 rs28483202 rs631815
rs6567401

1.00

0.08

0.22

0.22

0.09

rs1243064

0.08

1.00

0.34

0.73

0.82

rs2689416

0.22

0.34

1.00

0.29

0.32

rs28483202 0.22

0.73

0.29

1.00

0.73

rs631815

0.82

0.32

0.73

1.00

0.09
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CAUSAL MEDIATION PATHWAY ANALYSIS
In this chapter, the results from causal mediation analysis are presented. Based on
univariate regression analysis, tighter LD, more significant pleiotropic association and
functional annotation of likely causal variants in 3 loci with evidence for pleiotropic
associations with adiposity and inflammation, two variants including rs60505812 on
chromosome 3 and rs73093474 on chromosome 12were selected for in-depth causal
mediation analysis to distinguish variants with direct (biologic) from indirect (mediated)
pleiotropic effects. Results suggested rs60505812 may have direct and biologic association
with both adiposity and inflammation traits. The other variant, rs73093474, exhibit both
biologic and mediated pleiotropic effect on inflammation (via adiposity).
1. Background
Although GWAS have identified thousands of genetic variants associated with
phenotypic traits126, a variety of methodological issues281,334-338 have made understanding
the impacts of these findings in a biological context somewhat challenging339-341. The
difficulty identifying causal variants288 and pathways that mediate genetic effects342 have
been the two key barriers to the meaningful interpretation of genetic studies because only
a very small fraction of identified variants are causal311.
Despite the increased availability of fine-mapping tools for performing the localized
probing of genomic regions206,285,286, which has greatly contributed to pinpointing likely
causal variants, the functional follow-up necessary to determine the underpinning
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mechanisms that connect these causal variants with phenotypic expression lags
considerably behind343.
This gap between genetic association studies and the identification of the related
biological effects is an important issue, particularly when characterizing multi-potent
variants339. The added complexity of studying these prevalent344 but less well-characterized
‘pleiotropic’ variants127 is due to the existence of several models of associations345 that
each implies different types of functional effects.
As mentioned previously, based on the concept of “biologic” pleiotropy, a genomic locus
that is independently associated with several phenotypes would suggest that the genetic
effect is transmitted through a common pathway that is upstream of all associated
phenotypes127; however, pleiotropic effects can also be transmitted indirectly due to
relationships between the outcome phenotype and a “mediating” phenotype127. Elucidating
these complexities could provide novel biological insights to better understand the
biological pathways that underpin genotype-phenotype associations346, as well as disease
traits127, creating opportunities for improved clinical classification and drug repurposing.
In this study, a causal mediation pathway analysis211 of likely causal pleiotropic variants
was performed based on evidence of an association between adiposity and inflammation.
Mediation analysis provides a framework for distinguishing biologic from mediated
pleiotropy and for quantifying the proportion of total genetic effects on outcome
phenotypes347. This method was previously utilized to dissect the direct and indirect genetic
associations between SNPs and chronic obstructive disease (COPD)348, metabolic
syndromes349, mineral density350, and bladder cancer351.
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The aims of these analyses were to describe the associations between fine-mapped
variants identified on chromosomes 3, 12, and 18 with anthropometry and inflammationrelated phenotypes and distinguish whether the likely causal variants act directly (i.e.,
irrespective of any hypothesized mediator) or whether the association is predominately due
to correlations, with particular attention paid to the prevailing understanding of causal
inflammation and adiposity pathways352,353. To achieve these aims, a set of phenotyped and
genotyped subjects from the CCHC were examined.
2. Methods
2.1. Candidate variant set
A set of variants with posterior causal probability values > 0.5, located at three separate
loci on chromosomes 3, 12, and 18, were considered for the causal mediation analysis.
Variants were identified through a fine-mapping analysis performed on loci associated with
suggestive evidence for pleiotropy between anthropometry traits, including BMI, WHR,
and WC, and inflammation-related phenotypes CRP, fibrinogen, IL-6 and IL-8.
Pleiotropy assessments were completed using GWAS summary statistics during prior
steps, based on genomic measurements obtained from the participants in the CCHC study.
Additionally, the index variants for each locus, which exhibited the lowest pleiotropic pvalues and were used to configure the fine-mapping target regions, were also included in
the set.
There was a total of 25 variants likely causal variants across all 3 regions. SNP allelic
dosage for these selected variants were extracted from variant calling format (VCF)292 files.
Allele dosage is the estimated (expected) fractional and continuous counts of effect allele
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at each SNP for each individual, ranging continuously from 0 to 2, where a value of 2 for
a given variant indicated that the subject harbors both phenotype-increasing alleles,
whereas a value of 0 implies the complete absence of the risk allele.
2.2. Phenotypes
The last non-missing phenotypic recorded observations for BMI, WHR, WC, CRP, IL6, and IL-8 were extracted for all CCHC individuals whose genetic measurements were
used in the univariate GWAS and pleiotropy assessments analyzing the association
between anthropometry and inflammation. GWAS analyses similarly incorporated last
non-missing phenotypic recorded observation for each trait, as well as corresponding
covariates’ values for age and sex. Details on phenotype data collection methods were
presented in prior steps.
2.3. Covariate selection
A review of prior studies showed that several factors are likely to play significant roles
in obesity/adiposity and inflammation. In addition to age and sex354-356, variables such as
alcohol consumption and smoking357,358, physical activity359,360, hypertension361, lipid
profile362,363, and insulin sensitivity364 have been reported.
It is arguable that few of the enlisted factors, including lipid levels and blood pressure,
could act as the mediators of the association between adiposity and inflammatory
outcomes365,366 and not as the confounders. In the case of insulin resistance, although
studies have indicated causal associations, with adiposity serving as an outcome
predictor367,368, other assessments have indicated that the accumulation of visceral adipose
tissue could be a consequence of increased insulin resistance rather than a cause20,369.
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Therefore, in this study, the following covariates were incorporated into the mediation
models: homeostatic model assessment of insulin resistance (HOMA-IR), age (years), sex
(binary), alcohol consumption (oz/week), moderate to vigorous level of physical activity
(binary), current smoking status (binary), and ancestry principal components (to adjust for
population stratification). The alcohol level was obtained by tallying the average number
of alcoholic beverages consumed within a week, which was multiplied by 0.6 (or 0.48 for
wine, based on the National Institute of Alcohol Abuse and Alcoholism (niaaa.nih.gov)
formulation for the level of alcohol content in different beverages). A moderate to vigorous
level of physical activity was defined as 150 minutes of sweat-inducing activities in a week.
The values for covariates were taken from the same exam where primary phenotypes
were taken.
2.4. Statistical analysis
The list of fine-mapped-prioritized SNPs and index variants in the 3 target regions with
evidence for pleiotropy and their SNP dosage values were tested for univariate associations
with the study phenotypes (BMI, WC, WHR, CRP, IL-6, and IL-8) using linear regression
assuming an additive genetic effect.
Pairwise correlations were calculated between the index SNPs and variants with high
posterior causality probability values (with PLINK package370) to assess whether the finemapped variants are in LD with their respective index SNPs. Variants with the strongest
significant associations with phenotypes, in the tightest LD with the index SNPs, and
sharing functional features associated with adiposity- and inflammation-related tissues
were subsequently selected for causal mediation analysis.
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Analyses were limited to samples with non-missing observations for outcome
phenotypes. An exploratory analysis of the phenotypes showed the skewed distributions of
inflammatory markers; therefore, inflammation phenotypes were log-transformed
(supplementary Figure 6.1) because mediation analysis assumes the normal distribution of
outcomes. Some covariates, including physical activity, alcohol consumption, and smoking
status, were characterized by considerable missingness. Because mediation analysis only
uses complete cases, missing covariates were imputed using the predictive mean matching
(PMM)371 method. Subsequent mediation analyses were conducted with both an imputed
dataset (assuming missingness at random) and a reduced set that only included empirically
complete cases.
Directed acyclic graphs (DAGs) were used to conceptualize the biologic pathways of
associations (Supplementary Figure 6.2). Causal mediation analysis requires that the causal
model (i.e., the likely temporal sequence of phenotypes) be pre-specified. Causal models
were based on the prevailing knowledge of adiposity and inflammation associations (causal
directions) to determine the mediator and outcome phenotypes from each mediation
analysis.
2.5. Causal mediation pathway analysis
Under the biologic pleiotropy model, a likely causal variant is associated with multiple
phenotypes through distinct pathways (Supplementary Figure 5.3a). Therefore, the
directional association between the SNP and the outcome phenotype should be significant
(outside of the 95% error levels), once the association has been adjusted for the mediator
(phenotype) and the covariate effects; a lack of significant associations may suggest
mediated pleiotropy (Supplementary Figure 5.3b).
114

For this study, analyses were performed using the causal inference approach to mediation
analysis209, which allows for the assessment of whether an SNP has a direct effect on the
phenotype of interest or whether the SNP only acts through a secondary (correlated)
phenotype, in a sequential manner. Distinguishing the pleiotropic operational mode assists
in the identification of the biological pathways through which a genomic variant affects
multiple phenotypes.
The R package Mediation372 was used for analysis, which conducts a three-step process.
The total effect between an SNP and an outcome phenotype is assumed to be the sum of
the average causal mediation effects (ACMEs) and the average causal direct effect (ADE).
The first step includes estimating the distribution of the mediator phenotype as a function
of the SNP, adjusted for ancestry genetics (e.g., anthropometry ~ genotype + PCs). The
next step involves estimating the distribution of the outcome phenotype as a function of
the mediator phenotype, genotype, and covariates (e.g., inflammation marker ~ mediator +
genotype + PCs + covariates). The final step combines the fitted models in the mediation
equation, providing estimates and p-values for the direct (e.g., inflammation ~ SNP) and
indirect (via adiposity) associations.
Mediation analysis involved the stepwise selection of covariates during the second step.
The initial formulation (Model 1) included no covariates except ancestry PCs (e.g.,
inflammation marker ~ genotype + mediator + PCs). In subsequent models, age and sex
(Model 2), alcohol and physical activity (Model 3), smoking status (Model 4), and insulin
resistance (Model 5) were progressively added to assess the confounding effects of
covariates on the observed associations. Because no significant differences were observed
between the different adjusted models, only the final adjusted model was included in this
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report. No meaningful difference was observed between the results inferenced from the
imputed dataset and those based on the empirical observations. Therefore, models using
the multiple-imputation set were presented in the results section, and the results from the
empirical set can be found in the supplementary materials.
The number of simulations was set to 1,000, and models were calculated with robust
standard errors.
2.6. Sensitivity analysis

The empirical distributions of the covariates showed the presence of extreme
observations. Comparative analyses were conducted both with and without outliers to
assess whether the outcomes would differ.

For causal mediation analysis, the proposed sensitivity test in the Mediation R package
was used. This test relies on sequential ignorability212, which implies that after accounting
for an observed confounder, no unmeasured variable may confound any of the following:
1) genotype-mediator association, 2) genotype-outcome phenotype association, and 3)
mediator-outcome association.

The package passes the results from mediation analysis to medsens function. The
functions choses as the sensitivity parameter the correlation ρ between the residuals of the
mediator and outcome regressions. If there exist unmeasured confounder which affect
either the mediator or the outcome, it is expected that the sequential ignorability
assumption is violated and ρ is no longer zero. The sensitivity analysis is conducted by
varying the value of ρ and examining how the estimated ADE and/or ACME changes.
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The number of simulations used for the sensitivity test was set at 100, and correlation
parameter ρ increment was set at 0.1.

3. Results
The exploratory analysis of covariates (Table 5.1) showed elevated distribution of insulin
resistance [median =2.9 µIU/mL, interquartile range (IQR): 1.7, 4.8], a low proportion of
individuals reporting moderate to vigorous physical activity (approximately 24% of
participants), and current smokers being the majority of the cohort (55%). The empirical
distribution of insulin resistance values showed the presence of a few extreme measures
(Figure 5.1). The distributions of anthropometric measures indicated a high level of obesity
(>75% with BMI > 30 and WHR > 88) and high levels of inflammation markers (IL-6
median =2.7pg/dL, IQR:1.4, 4.8).
The set of variants with a high posterior probability of causality, including their
respective index variants, were fit into a linear regression with phenotypes as the outcome.
The results of the univariate analysis and pairwise LD-score with the lead pleiotropic
(index) variant for each region (Table 5.2) showed inconsistent patterns of associations
across phenotypes. In the target region on chromosome 3, only 5 out 10 variants were
associated with BMI, WC and WHR, 4 with CRP, 3 with IL-6, 2 with IL-8, and none with
fibrinogen, including the results from index SNP. Only 2 variants in the locus, rs605058102
and rs10514654, were significantly associated with 5 out of 6 phenotypes.
For the target region on chromosome 12, 5 of 9 variants were significantly associated
with BMI, WC and CRP, 6 with WHR, 1 with IL-6, 2 with fibrinogen, and none with IL8, including the results from the index SNP. However, 5 of 9 variants (rs60939199,
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rs60995491, rs73093474, rs10506239, and rs73094803) appeared to be associated with
multiple phenotypes, including BMI, WC, WHR, and CRP. For the target region on
chromosome 18, the results did not show any significant associations between phenotypes
and likely causal pleiotropic variants, except for the index SNP (rs4609952), which was
significantly associated with WHR (Table 5.2).
Based on the significant associations with multiple phenotypes identified in the
univariate regressions (Table 5.2), two variants were selected for in-depth causal mediation
pathway analysis due to tighter LD with their respective index SNPs, lower pleiotropic pvalues (Paspu), and adipose tissue regulatory features (Table 5.1a-b, prior chapter):
rs60505812, on chromosome 3 and rs73093474 on chromosome 12.
To distinguish biological pleiotropy from mediated pleiotropy, causal mediation analyses
were performed. Using DAGs, the regression results, and existing biological knowledge,
separate but methodologically identical models were used to assess the total effects
between the likely causal variants and the phenotypes of interest (Supplementary Figure
5.4).
For rs60505812 on chromosome 3, BMI was assumed to be the mediating phenotype,
and IL-6 was chosen as the outcome. The selection of associated phenotypes was guided
by univariate GWAS p-values. For this variant, no meaningful mediated effect was
observed [estimate = 0.01 (pg/dL) per risk allele, 95% confidence interval (95% CI): −0.01,
0.04; Table 5.3], but the direct effect was significant (estimate = 0.13 (pg/dL) per risk
allele, 95% CI: 0.05, 0.22) after adjusting for age, sex, the first 2 PCs, alcohol consumption,
physical activity, current smoking status, and insulin resistance level.
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For the variant rs73093474 on chromosome 12, WHR was the mediator, and CRP was
chosen as the outcome phenotype. Evidence supported both a mediated effect (estimate =
−0.02 (mg/L) per risk allele, 95% CI: −0.04, −0.00) and a direct effect between the SNP
and CRP (estimate = −0.16 (mg/L) per risk allele, 95% CI: −0.25, −0.06). This result
implies that the variant exhibits both biologic and mediated (via WHR) pleiotropy. These
results suggested that these two variants contributed to inflammation, independently of
adiposity.
The sensitivity analysis for unmeasured confounders (Figure 6.3) showed that
unmeasured cofounders were unlikely to unduly confound direct SNP-outcome-phenotype
associations for both variants, as the estimates were outside of the 95% CI for sensitivity
parameters. Finally, mediation analyses were performed, excluding samples that had
extremely high insulin resistance values. No tangible difference was observed; therefore,
no data points were excluded from this report.
4. Discussion
Pleiotropy assessments performed during prior steps identified loci with suggestive
evidence for multi-phenotype associations among CCHC participants. The functional
evaluation of likely causal variants, identified through fine-mapping in the prior steps,
revealed that the majority were nonsense-mediated (NMD) regulatory SNPs, underscoring
their potential for pleiotropic effects, particularly in the context of adiposity and
inflammation.
However, fine-mapping analysis is restricted to the assignment of causal probability
based on observed associations and functional annotations. Mediation analysis is an
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approach that can be utilized to model causal associations between variants with a high
probability of causality and phenotypic outcomes373. The characterization of pleiotropy
associations facilitates biological interpretations.
A total of 25 SNPs of likely causal variants, residing in three different regions, with
evidence of inflammation-adiposity pleiotropy effects, were considered for mediation
analysis. This set included three 3 index SNPs (i.e., the variants with the most significant
pleiotropic p-values in each target locus) and 22 variants that demonstrated high probability
of causality values during the fine-mapping analysis. LD analyses suggested that the
examined variants consisted of 4 distinct signals, two of which were located on
chromosome 12.
Based on the consistency of associations across multiple phenotypes, adiposity tissue
regulatory features, and tight LD with respective index SNPs, two variants, including
rs60505812 on chromosome 3 and rs73093474 on chromosome 12, merited in-depth
examination. None of the SNPs in the third region on chromosome 18 were associated with
any of the traits under the study.
Mediation analysis indicated that rs60505812 was independently associated with both
IL-6 and BMI, which are surrogates of inflammation and adiposity, respectively, even after
adjusting for age, sex, physical activity level, alcohol consumption, and current smoking
status (Table 6.3), which is consistent with biologic pleiotropy. However, no indirect
association was identified between the SNP and IL-6 [via BMI]; therefore, the model failed
to provide evidence for mediated pleiotropy.
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As indicated by functional analyses using bioinformatic tools in prior steps, rs60505812
is an NMD variant. NMDs, in general, play important roles in the reduction of gene
expression error by eliminating mRNAs that contain premature stop codons328. This variant
is located in an intronic region of the sulfatase modifying factor 1 (SUMF1) gene, which
is known to encode a similarly named enzyme that catalyzes steroid sulfates316. Although
no direct association between SUMF1 and metabolic traits has previously been reported,
variants in this gene have been suggested to be associated with inflammation318.
Additionally, steroid sulfates play a functional role in energy homeostasis and
inflammation319.
The functional assessment of rs60505812 with Haploreg demonstrated an annotation
with

histone H3 lysine 4 trimethylated (H3K4me3)374 in fetal adipose cell nuclei.

H3K4me3 promotes gene expression by altering the accessibility of genes to initiate
mRNA transcription
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. Whether this regulatory association and concurrent synergistic

phenotypic variation [with fat uptake and increased pro-inflammatory activities] is
promoted by common pathways at molecular, cellular or tissue levels require further
assessments. However, regulatory annotation with fetal nuclei would suggest functional
association with a wider range of metabolic processes, and therefore involving sub-cellular
‘foundational’ pathways.
For the variant rs73093474, on chromosome 12, mediation analysis indicated both a
direct association with CRP (Table 6.3) and an indirect association (via WHR) in the
covariate-adjusted models, which demonstrated concurrent biologic and mediated
pleiotropy. In contrast to rs60505812, this variant has a regulatory annotation with the
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mono-methylated H3K4me1-Enhancer in adipose cell nucleus, in addition to skeletal
muscle and brain tissues.
H3K4me1 is the primary modification used to predict whether an SNP is a potential
enhancer (booster) of the gene expression376. Therefore, the associated regulatory effect of
rs73093474 [or the signal it represents] may be biologically more specific than rs60505812,
and less likely to involve multipotent pathways that underpin a greater range of phenotypic
traits. Caution must be exercised because a concrete biological inference necessitates both
the replication of genetic associations in larger samples and experimental assessment.
This SNP is also an NMD variant, intronic to transmembrane 117 (TMEM117), which
encodes a similarly named protein. This gene has been associated with endoplasmic
reticulum stress (ER stress) and mitochondria-mediated apoptotic cell death322. Obesityinduced ER stress has been shown to induce inflammation in adipose tissue377.
In conclusion, mediation analysis showed that the observed pleiotropic associations in
two of three target regions are potentially biologic associations, in which the SNP affects
a common pathway upstream of both inflammation- and adiposity-related phenotypes.
However, evidence for mediated pleiotropy was also identified for rs73093474, which
suggested that this variant also affects inflammatory phenotypes via the promotion of
adiposity.
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5. Tables and Figures
Table 5.1. Distributions of the phenotypes and covariates in Cameron County Hispanic
Cohort (CCHC) among participants with non-missing values for either C-reactive Protein
(CRP) or interleukin (IL)-6.
Variable (unit)
Age (year)
Female, N(%)
IL6 (pg/dL)
CRP (mg/L)
BMI (kg/height^2)
Waist Circumference (cm)
WHR (Waist/Height x 100)
Alcohol (Oz/week)
Moderate to vigorous physical activity, N(%)
Current smoker, N(%)
Homa-IR* (uIU/mL)
* homeostatic insulin resistance
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Median [IQR]
47.0[34.0, 60.0]
1492(66)
2.7[1.4, 4.8]
3.9 [2.0, 7.7]
30.1[26.6, 34.3]
100.7 [92.5, 110.5]
92.9[88.0, 97.9]
0.0 [0.0, 0.6]
252(23.9)
578(55.0)
2.9[1.7, 4.8]

Sample Size
2247
2247
1316
1860
2237
2247
2245
1196
1054
1050
2123

Table 5.2. Univariate regression results with genetic variants as the outcomes and
phenotypes as predictors.

chr18:61578750

chr12:44481380

chr3:4150897

Locus

2*

Variant

Paspu

rs200671707

1.02E-06

rs35441937

3.28E-01

0.10

rs10510288

6.61E-03

rs6808934

BMI

CRP

IL6

IL8

FIB

WHR

WC

2.25

2.86

2.82

1.70

0.28

3.07

2.45

0.96

0.52

0.52

-1.15

0.37

-0.57

0.26

0.68

0.24

0.99

2.14

1.98

1.15

1.64

-0.30

2.57

2.48

9.34E-02

0.23

0.99

1.14

1.18

1.59

1.24

-0.79

1.86

1.36

rs2874822

1.35E-01

0.10

0.96

-0.62

-0.75

-0.57

-0.44

-0.62

-0.62

-0.57

rs60505812

1.28E-06

0.86

0.98

2.73

2.42

2.65

2.34

0.59

3.02

2.59

rs952644

9.20E-03

0.19

0.92

2.10

1.68

1.39

1.75

-0.19

2.46

2.49

rs2600116

9.48E-02

0.21

0.95

0.33

0.25

1.67

0.19

0.17

0.80

0.02

rs10514654

1.89E-06

0.86

0.95

2.75

2.60

2.96

2.20

0.11

2.83

2.73

rs6777465

7.47E-01

0.13

0.98

0.56

0.38

-0.91

-0.27

-0.19

0.19

0.91

rs60939199

1.56E-06

-2.50

-2.79

-1.25

-0.60

-0.87

-2.62

-3.28

rs277221

1.33E-03

0.00

0.08

0.33

0.16

-0.48

0.56

-1.58

2.89

0.20

rs440389

1.63E-01

0.02

0.49

-0.53

0.60

-1.95

0.04

-1.28

1.54

0.26

rs4251527

3.87E-03

0.00

0.07

-0.68

-0.93

0.99

-0.68

2.01

-1.53

-0.16

rs60995491

2.81E-06

0.87

0.94

-2.49

-2.85

-0.33

-0.79

-0.56

-3.32

-3.53

rs11182419

6.56E-01

0.00

1.00

-0.60

0.26

-0.71

1.83

2.34

-0.67

-0.83

rs73093474

2.81E-06

0.87

0.94

-2.50

-2.86

-0.33

-0.78

-0.56

-3.32

-3.53

rs10506239

3.35E-06

0.93

0.99

-2.42

-2.84

-1.16

-0.42

-0.57

-2.87

-3.36

rs73094803

6.26E-06

0.77

0.93

-2.51

-2.65

0.19

-1.06

-0.12

-3.19

-3.51

rs4609952

2.67E-05

0.73

0.02

-0.20

-1.14

0.31

2.35

-0.13

rs1243064

1.03E-02

0.21

0.97

-0.21

0.63

-0.50

0.54

-0.99

-0.81

-0.39

rs2689416

6.65E-03

0.30

0.99

0.25

0.18

0.05

-0.77

-0.12

1.31

0.03

rs28483202

4.48E-04

0.88

0.99

1.06

0.34

0.18

-1.40

0.38

1.87

0.01

rs6567401

4.40E-02

0.27

0.99

0.60

0.78

-0.26

-1.15

-0.32

1.53

0.41

rs631815

9.91E-03

0.32

1.00

0.75

0.23

0.45

-0.29

-0.47

1.06

0.21

R

d`

*R-squared and d` are measures of pairwise linkage disequilibrium (LD) with index SNP in locus
[highlighted with light gray]. Variants in tighter LD with their respective index single nucleotide variants
(SNV), having significant pleiotropy p-value (Paspu), significant association with multiple phenotypes and
regulatory annotation features associated with adipose tissue were selected for in-depth causal mediation
analysis [denoted by light blue color].
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Table 5.3. Causal mediation analysis for rs60505812 and rs73093474.
Estimate/variant

Mediated Effect (ACME)*
Direct Effect (ADE)**
Total Effect (TE)
Proportion Mediated

rs60505812
Adjusted Model
Estimate
95% CI
0.01
(-0.01, 0.04)
0.13
(0.05, 0.22)
0.14
(0.06, 0.23)
0.07
(-0.11, 0.29)

rs73093474
Adjusted Model
Estimate
95% CI
-0.02
(-0.04, -0.00)
-0.16
(-0.25, -0.06)
-0.18
(-0.27, -0.08)
0.12
(0.01, 0.32)

*ACME=average causal mediated effect. For the variant rs60505812, this pertains to the statistical
association between the SNP and the outcome phenotype (IL6), mediated through BMI. For the variant
rs73093474, the ACME indicates the association between the SNP and the outcome phenotype (CRP),
mediated through WHR.
**ADE=average direct effect. For the variant rs60505812, this pertains to direct association between the
SNP and the outcome phenotype (IL6), after adjusting for the mediator (BMI). For the variant rs73093474,
this indicates the direct association between the SNP and CRP after accounting for the mediator effect
(WHR). ADE is a measure for biologic pleiotropy.
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Figure 5.1. Sensitivity analysis of observed average mediation effect and average direct
effect for variants rs60505812 (lower row) and rs73093474 (top row). The 95%
confidence interval for average mediation effect with rs60505812 includes 0 value for
sensitivity parameter ρ but the confidence interval for average direct effect does not. For
rs73093474, both direct and mediated effects’ confidence intervals do not contain 0
value, suggesting robustness of associations to unmeasured confounders.
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6. Appendices
Supplementary Figure 5.1. Empirical and log-transformed distributions of inflammation
markers.

Supplementary Figure 5.2. Conceptual directed acyclic graph (DAG) used as the
framework for causal mediation analysis. This approach is based on general mediation
model (VanderWeele, T.J. & Vansteelandt)209.
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Supplementary Figure 5.3. Biologic pleiotropy indicates direct association with
multiple phenotypes (Figure a), while biologic pleiotropy is induced by phenotypic
correlation (Figure b); multi-mode pleiotropy is also plausible (Figure c). DE: direct
effect, ME: mediated effect, SNV: single nucleotide variant.

Supplementary Figure 5.4. Directed acyclic graphs (DAGs) used to formulate causal
mediation analysis for variants rs60505812 and rs73093474. For variant rs60505812,
BMI is proposed as the mediating phenotype and interleukin(IL)-6 as the outcome. For
the remaining variant, rs60505812, waist to hip ratio (WHR) was proposed as the
mediating phenotype and C-reactive protein (CRP) as the outcome.
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DISCUSSION
Obesity is one of the major public health crises of our time378,379 and has steadily
increased worldwide6, affecting urban and rural dwellers9, children and adults10, and men
and women alike9. Many factors have been associated with the increased incidence of
obesity, including increased access to cheap, high-calorie processed foods380, reduced
physical activity381, changes in the environment382, and increased exposure to chemicals383,
among other potential contributors. Increased obesity, particularly abdominal obesity19, has
been associated with the increased incidence of various adverse metabolic disorders17,18,384
including insulin resistance20, hypertensive blood pressure21, elevated lipid levels22, and
hormonal dysregulation18. These metabolic disorders, in turn, have been associated with
the increased susceptibility to cardiovascular diseases23.
1. Inflammation-adiposity association
The underlying mechanisms that link obesity to cardiovascular diseases remain subject
to debate50-52, and certain hypotheses, including insulin resistance-induced arterial
stiffness53 and kidney-promoted hemodynamic imbalances55, have received wider attention
than others. However, changes in the local distribution of nutrition-sensitive62 adipose
tissue (due to the increased accumulation of visceral fat)59 have been associated with
altered morphologic and hormonal profiles60,61, and the resulting upregulation in
inflammation68,69 is thought to be a root cause of a large proportion of metabolic disorders.
An increased number (hyperplasic) of enlarged (hypertrophic) adipocytes promotes the
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increased production of cytokines, including IL-6 and IL-878,79. Cytokines attract
macrophages81,82, which, in turn, can activate the intracellular signals responsible for
upregulating the innate immune response87 and trigger the inception of atheromatic
processes that seed arterial lipid plaque formation.
In contrast, compelling evidence has also suggested that insulin resistance88,89and
increased circulatory91 and hypothalamic inflammatory responses92,93 might precede the
development of obesity. An increase in inflammatory mediators has been shown to predict
future obesity outcomes385. These seemingly contradictory observations necessitate a more
nuanced exploration of the relationships between obesity and immunity.
2. Rule of genetics and ancestry in inflammation-adiposity association
Although some of these findings might merely reflect circular feedback mechanisms, the
complex natures of both phenotypic domains might also indicate the involvement of other
mechanisms. Changes in both adiposity and inflammation may be mediated by common
pathways, a proposition that is supported by the observed overlap between genetic variants
associated with both adiposity and inflammatory markers110,111,114-116. The observations of
increased inflammatory responses following the upregulation of adiposity gene
expression112,113 and weight-gain associated inflammatory gene activation118,119 further
support the idea that these pathways may share common mediators. The existence of
pervasive124 and multi-potent ‘pleiotropic genetic variants’122 have been hypothesized,
which could provide insight into the shared biology and pathophysiological processes that
underpin adverse cardiovascular events107 and inform phenotypical and clinical
classifications.
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However, potential pleiotropic variants have not yet been sufficiently explored.
Methodological issues, including difficulties distinguishing biologic pleiotropy (in which
a genetic locus is independently associated with multiple phenotypes) from mediated
pleiotropy (in which a genetic locus is correlated with a phenotype but may not be
causal)127,

ascertainment

bias

due

to

co-occurring

traits135,

phenotypic

misclassifications136, variations in allelic structures, or difficulty to identify shared
controls137, and ambiguity when a causal variant is identified as a regulatory, non-coding
SNP138, can all pose significant barriers to identifying share pleiotropic regulators. The
most important challenge has been the limited inferential utility of variants identified
through GWAS for pleiotropy testing. A disproportionately large proportion of existing
GWAS have been performed on largely European ancestry populations139,140.
The significance of genetic architecture can be further highlighted by the differential
distributions of adiposity and inflammation among distinct genetic ancestry groups that are
otherwise comparable142-144. Hispanics/Latino (HLA) populations, in particular, have been
noted to present an increased incidence of cardiometabolic abnormalities145, with a diabetes
prevalence that is 2.5-fold the level reported among non-Hispanic Whites (NHW)25, and 2
in 3 HLA adults present with abnormal lipid levels26.
Although some of this discrepancy could be explained by an increased prevalence of the
obesity11,14, differences in inflammation levels have persisted, even in adiposity-adjusted
analyses142,146. These disparities extend to the “Hispanic paradox”, in which the
cardiovascular mortality rate among this population is lower than other populations, despite
elevated metabolic risk factors27,28 and have not yet been sufficiently explained by other

131

contributing factors30,33. These findings underscore the need to re-focus on the important
but sparsely explored contribution of genetics to obesity and inflammation interaction34.
3. Study object
The aims of this study were: to identify genetic loci with potential evidence of pleiotropic
effects across inflammatory factors, including CRP, IL-6, IL8, and fibrinogen, overall
obesity (BMI), and central adiposity (WC & WHR) domains, in an HLA population (Aim
1); to fine-map potential pleiotropic loci and distinguish likely causal variants (Aim 2); and
to evaluate whether observed signals demonstrate independent associations with both
phenotypic domains (i.e., biologic pleiotropy) or whether the association is induced via
phenotypic correlations (i.e., mediated pleiotropy, Aim 3).
4. Cameron County Hispanic Cohort
The population examined in this study was the CCHC. Most of these participants selfidentify as Mexican Americans. This cohort is characterized by a high prevalence of
obesity and cardiometabolic abnormalities166,167, with increased susceptibility to adverse
health events. The prevalence of obesity in this population was higher than the national
HLA average, as reported by the CDC for the 2017–2018 period275 (45% nationally vs.
>75% in this study).
A total of 3,313 samples were examined in this study. The number of SNPs identified for
genetic testing was >9 million. Analyses of ancestry PCs showed that the majority of PCs
clustered predominantly with Mexican populations, with fewer individuals aligning with
other ethnic groups.
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5. Genetic signals
The GWAS analyses showed that two regions on chromosomes 6 and 8 exceeded the
GWAS significance level (p-value < 5 × 10−8) for sex-combined meta-analyzed WHR
results; the GWAS-identified significant SNPs in the novel locus are located in regions
near LRFN2 and LOC101929555, and have not been previously recorded in GWAS
libraries. Variants in LRFN2 have been positively associated with BMI257,258, type 2
diabetes259, lipid profiles260, cognitive abilities261, and WHR262.
The absence of GWAS-identified significant associations in regions that have been
widely reported to be associated with anthropometric and inflammatory traits263,264 may be
the result of ancestry-specific patterns, similar to findings from other studies that have
reported ethnic differences in genetic associations268-271. However, caution must be
exercised when making any inferences because differences in the LD structure239,
statistical power238, and SNP coverage272 among studies can all induce variations in the
GWAS signal.
6. Evidence for pleiotropy
Pleiotropy assessments were performed using the aSPU199 testing method. Although no
pleiotropic signals were observed at the GWAS significance level, at least five signals, on
chromosomes 1, 3, 12, 18 and 19, were identified that suggested the presence of SNPs with
strong pleiotropic p-values (< 5 × 10−6). Although the signals on chromosomes 1 and 19
were driven by solitary variants in each instance, the suggestive loci in the remaining three
chromosomes were robust to sensitivity analyses and contained clusters of SNPs with
strong pleiotropy p-values.
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A review of the GWAS catalogue revealed an extensive number of variants with varying
degree of LD with SNPs within the three suspected pleiotropic regions that were previously
reported in association with a range of metabolic traits. All three regions contained variants
associated with inflammatory diseases, anthropometric measures, and energy intake.
Additionally, for the loci identified on chromosome 3, a considerable number of variants
were in LD with variant in the region that were previously identified for brain functions
and neurological diseases.
The fine-mapping of these three suspected pleiotropic regions (on chromosomes 3, 12,
and 18) was performed, incorporating the summary statistics from pleiotropy analyses, LD
structures, and functional annotations with regulatory and coding features293,294, which
distinguished 22 variants with posterior causality probabilities greater than 50% among the
7,326 total variants assessed across all 3 regions.
None of the index SNPs, which had the most significant pleiotropy p-values, were
identified among the credible causal variant sets in each region, which could be due to
several possibilities, including the high correlation with several significant variants, the
index SNP serving as a proxy for the true ‘causal variant’312, interactions with distant
topologically associated domain (TAD)313 variants, or the presence of multiple signals.
However, a potential second (independent) signal was only observed for the suspected
pleiotropic locus identified on chromosome 18.
7. Characteristics of likely pleiotropic signals
The clear majority of likely causal variants identified in each of the three regions were
intronic, nonsense-mediated decay (NMD) variants, which overlapped with six different
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genes, including sulfatase-modifying factor 1 (SUMF1) on chromosome 3, interleukin 1associated receptor kinase (IRAK4) and transmembrane 117 (TMEM117) on chromosome
12, and serpin family B 10 (SERPINB10), SERPINB2, and histocompatibility minor serpin
domain-containing (HMSD) on chromosome 18.
NMD variants play regulatory roles, quality-checking gene expression errors by
eliminating messenger ribonucleotide (mRNA) molecules that contain premature
termination codons328. Growing evidence has suggested that variations and tissue-specific
differences in NMDs can alter the underlying pathologies of genetic diseases329-331.
Notably, interactions between NMDs and protein-coding variants have been linked with
an increased risk of developing obesity and type 2 diabetes, as reported in one recent transancestry cohort332. For instance, in a clinical study, a patient with early-onset obesity was
characterized with a mutation-induced malfunction of the NMD surveillance pathway,
which affected Pro-opiomelanocortin (POMC) gene regulation; this gene is involved in a
wide range of activities, including body-weight regulation333. The results from this study
further underscored the importance of NMD variants in the context of pleiotropy.
Pleiotropy association studies cannot distinguish whether an observed association
between a genetic variant and a phenotype occurs due to direct (i.e., biologic pleiotropy)
or indirect effects (i.e., mediated pleiotropy) due to phenotypic correlations with the
primary trait. Mediation analysis refers to a type of conditional analysis, in which the total
effect between a predictor and an outcome is divided among several factors that contribute
to the association and relies on counterfactual principles208. Using this framework, the
causal effects can be viewed as the difference between two potential phenotypic outcomes,
depending on whether an individual harbors the risk alleles (at the same time).
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In addition to the 3 identified index SNPs, which featured the lowest pleiotropic p-values
for each locus with evidence for pleiotropy, all 22 fine-mapped variants with high posterior
causality probabilities were fit into univariate regression models using the phenotypes as
predictors. Those variants in tighter LD with their respective index SNPs exhibited
consistent and significant associations with multiple phenotypes in these univariate
regressions, and those with the lowest pleiotropic p-values and regulatory features
associated with adipose tissue were selected for in-depth causal mediation analysis.
The mediation analysis indicated that rs60505812 was independently associated with
both an inflammatory marker (IL-6) and an adiposity measure (BMI), even after adjusting
for potential confounders like age, sex, physical activity level, alcohol consumption, and
current smoking status, which is consistent with the biologic pleiotropy model.
Although no direct association between SUMF1 and metabolic traits has previously been
reported, variants in this gene have been suggested to be associated with inflammatory
diseases, including chronic obstructive pulmonary disease (COPD)318. Additionally,
steroid sulfates play functional roles in energy homeostasis and inflammation319. The
overexpression of human steroid sulfatase in the adipose tissue of transgenic male mice
and female mice that underwent ovariectomy exacerbated metabolic phenotypes, resulting
in weight gain and the accumulation of fat mass, worsened insulin sensitivity, and altered
energy expenditures386.
8. The functional evaluation of likely pleiotropic variants
The functional assessment of rs60505812 with Haploreg demonstrated an annotation
associated with histone 3 lysine 4 trimethylated (H3K4me3)374 in fetal adipose cell nuclei.
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H3K4me3 regulates gene expression by altering the accessibility of genes to promote
mRNA transcription375 and has generally been associated with actively transcribed genes
in animal models387. H3K4me3 is also known to play a significant role in the genetic
regulation of stem cell potency387. H3K4me3 has been extensively observed on
nucleosomes at the 5’ end of eukaryotic genes undergoing active transcription by RNA
polymerase II388. A regulatory annotation in fetal nuclei would suggest functional
associations with pathway(s) upstream to a wide range of metabolic traits, resulting in
pleiotropic properties at protein or variant levels. However, further assessments remain
necessary to establish the precise level at which the suggestive signal operates.
For the variant rs73093474, on chromosome 12, mediation analysis indicated both a
direct association with CRP (Table 6.3) and an indirect association (via WHR) in the
covariate-adjusted models, which demonstrated concurrent biologic and mediated
pleiotropy. In contrast with rs60505812, rs73094374 has a regulatory annotation with the
mono-methylated H3K4me1-enhancer in adipose cell nuclei, in addition to skeletal muscle
and brain tissues. H3K4me1 is the primary modification used to predict whether an
identified SNP is a potential enhancer (booster) of gene expression376.
This SNP was also an NMD variant, intronic to transmembrane 117 (TMEM117), which
encodes a similarly named protein. This gene has been associated with endoplasmic
reticulum stress (ER-stress) and mitochondria-mediated apoptotic cell death322. Obesityinduced ER-stress has been shown to induce inflammation in adipose tissue377. In
experimental studies examining mice, sustained fat accumulation interrupted ER
homeostasis and induced the unfolded protein response (UPR)389. Unfolded proteins within
the ER lumen activate the ER stress pathway390, and lipid-sensitive transmembrane
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proteins act as sensors for unfolded proteins391,392. Elevated levels of UPR activation have
been observed in adipose tissue from obese individuals393 and has been suggested to serve
as a potential mechanism that might link obesity with inflammation and insulin
resistance394,395.
The regulatory annotation associated with H3K4me1 combined with the suggested
association with UPR-induced ER-stress activity in adipocytes suggest that the biological
effects of rs73093474 (or the signals it represents) may be relatively tissue-specific,
compared with those for rs60505812, and less likely to act upon multipotent pathways.
Further genetic and functional studies in larger settings and varied populations are
warranted before concrete biological inferences are made.
9. Study strengths and limitations
The present study had notable limitations. The sample size used for this study was small.
Adiposity and inflammation traits are highly polygenic and, therefore, the effect of any
given genetic variant on the overall phenotype is small, and adequate statistical power is
necessary to isolate signals. GWAS performed in larger samples present considerably
improved detection power compared with smaller samples396. The general absence of
significant GWAS results in this study can largely be attributed to insufficient detection
power. However, the study incorporated a pleiotropy test that served the dual aims of
evaluating pleiotropy among correlated phenotypes and increasing the statistical power for
locus discovery. Previous studies have illustrated133,397-399 that harnessing pleiotropy could
successfully increase statistical power.
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Although this study only included a discovery cohort, the analysis did account for
multiple factors that could affect the generalizability of observed signals400, including each
variant’s effective sample size and ancestry architecture401. Furthermore, low frequency
and rare variants with MAF <5% , were excluded from the analysis to improve the
likelihood of replicability.
The study could not distinguish whether suggestive pleiotropic signals acted at specific
levels or were associated with multi-potent pathways that affected a wider range of
phenotypic traits. Generally, trans-regulatory SNPs act at the variant level, whereas cisregulatory and coding SNPs act at the protein (i.e., gene) and tissue levels402. The precise
characterization of pleiotropic signals requires insight from expression quantitative trait
(eQTL) analysis which seeks to examine SNPs that affect the mRNA expression levels, or
more relevently candidate SNP-mRNA study. However, functional annotation evaluation
was able to provide suggestive evidence for possible functional roles associated with likely
causal variants. For instance, the fetal nuclei H3K4me3 annotation for rs60505812 was
suggestive of potential pleiotropic effects at either variant or protein levels.
The present study also had major strengths. This study is the first comprehensive
assessment of pleiotropy relationships between adiposity and inflammation traits in an
HLA or any population. The results provided suggestive evidence for the regulatory effects
of identified genetic variants on metabolic pathways and highlighted the complexity and
interrelatedness of seemingly independent phenotypic traits.
The intentional selection of a genetically tri-admixed HLA population151 with shorter
haplotypes compared with European ancestry (EA) populations155 presented opportunities
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for precise fine-mapping154, which greatly reduced the number of SNPs identified for
causal evaluations157,158.
Rigorous association tests, which incorporated pairwise kinship structures, improved
genetic associations’ estimates. The integrative analytical framework that was used for this
study is innovative; and the combination of various steps, including GWAS, pleiotropy
assessments, fine-mapping, functional evaluations, and causal mediation analysis
collectively improved the biological interpretation of the results.
10.

Study summary and conclusion

The characterization of overlapping genetic pleiotropy between inflammatory and
adiposity pathways is essential for improving our understanding of the etiology of the
various metabolic pathways that regulate cardiovascular disease development. This
research provided a systematic assessment of potential variants that exert pleiotropic
effects on inflammatory and adiposity traits. The analysis distinguished a novel locus on
chromosome 6 associated with WHR outcomes in sex-combined results.
The examination of 3 loci with suggested pleiotropy resulted in the isolation of 22
variants with high posterior causal probabilities, including 2 SNPs on chromosomes 3
(rs60505812) and 12 (rs73093474) that exhibited regulatory features associated with
adipose tissue. The identification of likely pleiotropic variants indicated that 1) a
considerable degree of overlapping genetic pleiotropy exists between adiposity and
inflammation, and 2) evidence exists to support both the direct and independent pleiotropic
effects of likely causal variants on both phenotypic domains, in addition to the potential
mediated pleiotropy.
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The results showed the potential of these genetic variants to provide biological insight,
which might inform the development of preventive and clinical strategies intended to
improve the cardiovascular outcomes of HLA populations, and by extension, improve
targeted healthcare for all ethnic group in this era of precision medicine.
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